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1. Introduction 
Acquired immunodeficiency syndrome (AIDS) was firstly recognized as a new disease in 
the United States when clinicians in New York, Los Angeles and San Francisco began to see 
young, homosexual men with Pneumocystis carinii (now Pneumocystis jiroveci) pneumonia 
and Kaposi's sarcoma, unusual diseases for young adults not known to be immunosuppressed. 
The first report in the medical literature that alerted the world to this new immunodeficiency 
syndrome appeared in June of 1981 and described five young, homosexual men in Los 
Angeles with Pneumocystis carinii pneumonia.1 That observation was followed a few weeks 
later by a report of 26 homosexual men, from both New York and San Francisco, with 
Kaposi's sarcoma (four of whom also had Pneumocystis carinii pneumonia).2 Other reports 
followed of a similar syndrome in injecting drug users.3 All of these individuals shared a 
profound immunodeficiency, the hallmark of which was a depletion of CD4-positive, or T-
helper, lymphocytes. In mid-1982, the Centers for Disease Control (CDC) reported on 
Pneumocystis carinii pneumonia among persons with hemophilia.5 For a short time, the new 
disease was called gay-related immunodeficiency syndrome (GRIDS), but by September of 
1982, the CDC had published a case definition, using the current designation of acquired 
immune deficiency syndrome (AIDS) in print, and it was rapidly adopted by researchers.6  
The prominence of homosexual men and injecting drug users in the early cases of AIDS 
suggested an agent that was both blood borne and sexually transmitted, although early 
speculation about the etiology of AIDS included the hypothesis that all the patients were 
immunosuppressed because they had a history of drug use or multiple sexually transmitted 
diseases or malnutrition (the “immune overload” hypothesis).7 The majority of researchers 
thought that the likely agent was a sexually transmitted virus that would be found in the 
peripheral blood. In Pasteur institute research group, guided by Luc Montagnier, on a lymph 
node biopsy, from one young gay man with lymphadenopathy in the neck, François Brun-
Vezinet with François Barrè-Sinoussi, after dissociated the node into single cells, and cultured 
the T lymphocytes discovered Reverse Transcriptase (RT) trace. The only then known were 
the human T cell leukemia viruses HTLV-1 HTLV-2, identified by Gallo’s group. 
Interestingly new isolated virus doesn’t precipitated by HTLV antibodies. This was the first 
evidence of retrovirus was agent of AIDS disease. Repeating analysis on biopsy’s cells of 
young hemophiliac man with evidence Kaposi’s sarcoma, a virus was isolated and cultured in 
patient’s T lymphocytes killing them as T lymphocytes cells from blood donors. Electron 
microscopic analysis showed that HTLV and new virus weren’t the same. 
HIV was first isolated in France in 1983 by Françoise Barré-Sinoussi as 
lymphadenopathy-associated virus (LAV),8 but strong evidence that it was the AIDS virus did 
not appear until 1984, when four papers were published in one issue of Science by Robert 
Gallo and colleagues, who designated their isolate HTLV-III.9 The International Committee 
on the Taxonomy of Viruses chose the designation human immunodeficiency virus (HIV) in 
1986. With the discovery by Montaignier's group in late 1986 of the related HIV-2 virus in 
West Africa, the original virus became HIV-1.11  
Four years ago blood test becomes commercially available, reducing almost to zero AIDS 
transfusion transmission risks. In 1978 the first anti-HIV drug, AZT, was introduced and with 
the discovery of protease inhibitors and HAART therapy (1996) many patient are living 
today12.  
In the twenty-five years since the initial discovery that AIDS is caused by HIV, the disease 
has grown into a global pandemic. At the end of 2007, the Joint United Nation Programme on 
HIV/AIDS (UNAIDS) reported more than 4 millions infection new cases, bringing the world-
wide number of HIV-infected individuals up to more than 40 million13.  
 
2. Molecular virology of HIV 
HIV is a lentivirus, from the family of retroviruses, which characteristically have an RNA 
genome contained within a capsid and a lipid envelope (Figure 1). 
2.1 Viral structure 
The viral envelope, a bi-layered membrane derived from the host cell, contains 2 major 
viral glycoproteins, gp41 and gp120. These originate from enzymatic cleavage of the larger 
viral pre-protein gp160; they mediate viral entry and syncytium formation. Gp120 has a 
variable protein domain containing the V3 loop, which elicits a strong immune response.14 
The HIV core is composed of 3 structural proteins, p24, p16, and p9. The p24 protein forms 
the capsid that encloses 2 genomic RNA strands and the viral enzymes reverse transcriptase, 
protease, ribonuclease, and integrase. The matrix protein, gp16, is anchored to the internal 
face of the envelope. P9 is a nucleocapsid protein not covalently attached to the viral RNA.15 
The genome of HIV, similar to retroviruses in general, contains three major genes: gag, 
pol, and env. These genes code for the major structural and functional components of HIV, 
including envelope proteins and reverse transcriptase. The major structural components coded 
by env include the envelope glycoproteins, including the outer envelope glycoprotein gp120 
and transmembrane glycoprotein gp41 derived from glycoprotein precursor gp160. Major 
components coded by the gag gene include core nucleocapsid proteins p55, p40, p24 (capsid, 
or “core" antigen), p17(matrix), and p7 (nucleocapsid); the important proteins coded by pol 
are the enzyme proteins p66 and p51 (reverse transcriptase), p11 (protease), and p32 
(integrase).16 
Accessory genes carried by HIV include tat, rev, nef, vif, vpr, and vpu (for HIV-1) or vpx 
(for HIV-2). The functions of some of these genes are known. The tat gene produces a regulatory 
protein that speeds up transcription of the HIV provirus. The rev gene encodes for a regulatory 
protein which switches the processing of viral RNA transcripts to a pattern that predominates with 
established infection, leading to production of viral structural and enzymatic proteins. The nef 
gene produces a regulatory protein that modifies the infected cell to make it more suitable for 
producing HIV virions. The vif, vpr, and vpu genes encode proteins that appear to play a role in 
generating infectivity and pathologic effects. Figure 2 shows an overview of the organization of 
the (approximately) 9-kilobase genome of the HIV provirus and a summary of the functions of its 
nine genes encoding 15 proteins17. 
 
 
 Figure 1. HIV structure. 
2.2 Mechanism of replication 
HIV life cycle (Figure 3) starts when the virus enters lymphocytes and monocytes through 
cognate recognition of the viral glycoprotein gp120 with the cell surface CD4 molecule and a 
chemokine receptor (either CXCR4 or CCR5).18,19 The two viral envelope proteins, gp120 and 
gp41, are conformationally associated to form a trimeric functional unit consisting of three 
molecules of gp120 exposed on the virion surface and associated with three molecules of gp41 
inserted into the viral lipid membrane. Trimeric gp120 on the surface of the virion binds CD4 on 
the surface of the target cell, inducing a conformational change in the envelope proteins that in 
turn allows binding of the virion to a specific subset of chemokine receptors on the cell surface 
(Figure 4). These receptors normally play a role in chemoattraction, in which hematopoietic cells 
move along chemokine gradients to specific sites. Although these receptors, which contain seven 
membrane-spanning domains, normally transducer signals through G proteins, signaling is not  
required for HIV infection.20 
The binding of surface gp120, CD4, and the chemokine coreceptors produces an 
additional radical conformational change in gp41. Assembled as a trimer on the virion 
membrane, this coiled-coil protein springs open, projecting three peptide fusion domains that 
“harpoon” the lipid bilayer of the target cell. The fusion domains then form hairpin-like 
structures that draw the virion and cell membranes together to promote fusion, leading to the 
release of the viral core into the cell interior.21 
HIV virions can also enter cells by endocytosis. Usually, productive infection does not 
result, presumably reflecting inactivation of these virions within endosomes. However, a 
special form of endocytosis has been demonstrated in submucosal dendritic cells. These cells, 
which normally process and present antigens to immune cells, express a specialized 
attachment structure termed DC-SIGN.22 This C-type lectin binds HIV gp120 with high 
affinity but does not trigger the conformational changes required for fusion. Instead, virions 
bound to DC-SIGN are internalized into an acidic compartment and subsequently displayed 
on the cell surface after the dendritic cell has matured and migrated to regional lymph nodes, 
where it engages T cells. Thus, dendritic cells expressing DC-SIGN appear to act as “Trojan 
horses” facilitating the spread of HIV from mucosal surfaces to T cells in lymphatic organs.23 
 
 
Figure 2. Organization of the HIV proviral genome and summary of gene product 
functions. 
  
On the basis of cell tropism, HIV strains can be broadly divided into 2 categories, 
macrophage-tropic (M-tropic) and T-cell tropic (T-tropic).  
M-tropic strains use CCR5 as a coreceptor and are referred as R5 viruses. They primarily 
infect macrophages and primary T cells and infect poorly CD4+ T-cell lines. In addition, these 
viruses tend to be transmitted sexually more easily.24 T-tropic strains use the CXCR4 
coreceptor, which is most expressed in CD4+ T cells. Also referred as X4 viruses, they induce 
the formation of syncytia in the infected cells25. Early in the course of HIV infection, the R5 
strain viruses predominate, but eventually both X4 and R5 strains are recovered. Mutations in 
the CCR5 gene protect cells from HIV infection. These mutations have not shown to be 
deleterious, probably because other chemokine receptors replace CCR5 functions. The level of 
expression of chemokine receptors also determines the ability of HIV strains to infect host 
cells. Recently, a primary HIV isolate has been reported to enter T cells using the CD8 
molecule, not requiring CD4 or chemokine receptor expression.26  
 
 Figure 3. HIV life cycle. 
 
Once inside the cell, the virion undergoes uncoating, likely while still associated with the 
plasma membrane (Figure 4). This poorly understood process may involve phosphorylation of 
viral matrix proteins by a mitogen-activated protein (MAP) kinase and additional actions of 
cyclophilin A and the viral proteins Nef and Vif. Nef associates with a universal proton pump, 
V-ATPase, which could promote uncoating by inducing local changes in pH in a manner 
similar to that of the M2 protein of influenza.18 After the virion is uncoated, the viral reverse 
transcription complex is released from the plasma membrane.26 This complex includes the 
diploid viral RNA genome, lysine transfer RNA (tRNALys) which acts as a primer for reverse 
transcription, viral reverse transcriptase, integrase, matrix and nucleocapsid proteins, viral 
protein R (Vpr), and various host proteins. The reverse transcription complex docks with actin 
microfilaments28. This interaction, mediated by the phosphorylated matrix, is required for 
efficient viral DNA synthesis. By overcoming destabilizing effects of a recently identified 
protein termed CEM15/APOBEC3G, Vif stabilizes the reverse transcription complex in most 
human cells.26-28 
 
 Figure 4. Early events occurring after HIV infection of a susceptible target cell. 
 
The viral RNA is reverse-transcribed into complementary DNA (cDNA) by the virus 
reverse transcriptase through use of a cellular lysine tRNA molecule as a primer; 
subsequently, the RNAase activity of the reverse transcriptase degrades the viral RNA 
template. The reverse transcriptase incorporates an incorrect nucleotide every 1500 to 4000 
bases, which explains the rapid occurrence of mutations. Some of the resulting mutations 
provide a survival advantage, leading to drug-resistant strains.23  
Reverse transcription yields the HIV preintegration complex (PIC), composed of double-
stranded viral cDNA, integrase, matrix, Vpr, reverse transcriptase, and the high mobility 
group DNA-binding cellular protein HMGI(Y). The PIC may move toward the nucleus by 
using microtubules as a conduit.30 
Unlike most animal retroviruses, HIV can infect nondividing cells, such as terminally 
differentiated macrophages. This requires an ability to cross the intact nuclear membrane. 
With a Stokes radius of approximately 28 nm or roughly the size of a ribosome, the PIC is 
roughly twice as large as the maximal diameter of the central aqueous channel in the nuclear 
pore. The 3 µm contour length of viral DNA must undergo significant compaction, and the 
import process must involve considerable molecular gymnastics.31  
One of the most contentious areas of HIV research involves the identification of key viral 
proteins that mediate the nuclear import of the PIC. Integrase, matrix, and Vpr have been 
implicated (Figure 4). Because plus-strand synthesis is discontinuous in reverse transcription, 
a triple helical DNA domain or “DNA flap” results that may bind a host protein containing a 
nuclear targeting signal.32 Matrix contains a canonical nuclear localization signal that is 
recognized by the importins  and , which are components of the classical nuclear import 
pathway. However, a recent publication calls into question the contributions both of the 
nuclear import signal in integrase and of the DNA flap to the nuclear uptake of the PIC.31 The 
HIV Vpr gene product contains at least three noncanonical nuclear targeting signals. Vpr may 
bypass the importin system altogether, perhaps mediating the direct docking of the PIC with 
one or more components of the nuclear pore complex. The multiple nuclear targeting signals 
within the PIC may function in a cooperative manner or play larger roles individually in 
different target cells. For example, while Vpr is not needed for infection of nondividing, 
resting T cells, it enhances viral infection in nondividing macrophages.35 The finding that both 
matrix and Vpr shuttle between the nucleus and cytoplasm explains their availability for 
incorporation into new virions.36 
Once inside the nucleus, the viral PIC can establish a functional provirus (Figure 4). 
Integration of double-stranded viral DNA into the host chromosome is mediated by integrase, 
which binds the ends of the viral DNA. The host proteins HMGI(Y) and barrier to 
autointegration (BAF) are required for efficient integration, although their precise functions 
remain unknown. Integrase removes terminal nucleotides from the viral DNA, producing a 
two-base recess and thereby correcting the ragged ends generated by the terminal transferase 
activity of reverse transcriptase. Integrase also catalyzes the subsequent joining reaction that 
establishes the HIV provirus within the chromosome.29  
Not all PICs that enter the nucleus result in a functional provirus. The ends of the viral 
DNA may be joined to form a 2-LTR circle containing long terminal repeat sequences from 
both ends of the viral genome, or the viral genome may undergo homologous recombination 
yielding a single-LTR circle. Finally, the viral DNA may auto-integrate into itself, producing 
a rearranged circular structure. Although some circular forms may direct the synthesis of the 
transcriptional transactivator Tat or the accessory protein Nef, none produces infectious 
virus.37 In a normal cellular response to DNA fragments, the nonhomologous end-joining 
(NHEJ) system may form 2-LTR circles to protect the cell.38 This system is responsible for 
rapid repair of double-strand breaks, thereby preventing an apoptotic response. A single 
double-strand break within the cell can induce G1 cell-cycle arrest. The ability of the free ends 
of the viral DNA to mimic such double-strand chromosomal breaks may contribute to the 
direct cytopathic effects observed with HIV.  
Integration can lead to latent or transcriptionally active forms of infection. Moreover, 
despite a vigorous immune response early in infection, these silent proviruses are a reservoir 
that allows reemergence of HIV when the body's defenses grow weaker.  
The chromosomal environment likely shapes the transcriptional activity of the provirus.39 
For example; proviral integration into repressed heterochromatin might result in latency 
(Figure 5). Other causes of latency may include cell type differences in the availability of 
activators that bind to the transcriptional enhancer in the HIV LTR or the lack of Tat. 
However, of the multiple copies of provirus that are usually integrated in a given infected cell, 
at least one is likely to be transcriptionally active. This fact may explain why the number of 
latently infected cells in infected patients is small.  
In the host genome, the 5´ LTR functions like other eukaryotic transcriptional units. It 
contains downstream and upstream promoter elements, which include the initiator (Inr), 
TATA-box (T), and three Sp1 sites 40. These regions help position the RNA polymerase II 
(RNAPII) at the site of initiation of transcription and to assemble the preinitiation 
complex. Slightly upstream of the promoter is the transcriptional enhancer, which in HIV-
1 binds nuclear factor kB (NFkB), nuclear factor of activated T cells (NFAT), and Ets 
family members.41 NFkB and NFAT relocalize to the nucleus after cellular activation. 
NFkB is liberated from its cytoplasmic inhibitor, IkB, by stimulus-coupled 
phosphorylation, ubiquitination, and proteosomal degradation of the inhibitor. NFAT is 
dephosphorylated by calcineurin (a reaction inhibited by cyclosporin A) and, after its 
nuclear import, assembles with AP1 to form the fully active transcriptional complex. 
NFkB, which is composed of p50 and p65 (RelA) subunits, increases the rates of initiation 
and elongation of viral transcription.42 Since NFkB is activated after several antigen-
specific and cytokine-mediated events, it may play a key role in rousing transcriptionally 
silent proviruses.  
 
 
 
Figure 5. Mechanisms of post-integration latency. 
 
When these factors engage the LTR, transcription begins, but in the absence of Tat 
described below the polymerase fails to elongate efficiently along the viral genome 
(Figure 5). In the process, short nonpolyadenylated transcripts are synthesized, which are 
stable and persist in cells due to the formation of an RNA stem loop called the 
transactivation response (TAR) element.43  
Tat significantly increases the rate of viral gene expression. With cyclin T1 (CycT1), 
Tat binds to the TAR RNA stem-loop structure and recruits the cellular cyclin-dependent 
kinase 9 (Cdk9) to the HIV LTR (Figure 5). Within the positive transcription elongation 
factor b (P-TEFb) complex, Cdk9 phosphorylates the C-terminal domain of RNAPII, 
marking the transition from initiation to elongation of eukaryotic transcription.44 Other 
targets of P-TEFb include negative transcription elongation factors (N-TEF), such as the 
DRB-sensitivity inducing (DSIF) and negative elongation (NELF) factors.44 The high 
efficiency with which the HIV LTR attracts these negative transcription factors in vivo 
may explain why the LTR is a poor promoter in the absence of Tat. The arginine-rich 
motif (ARM) within Tat binds the 5’ bulge region in TAR. A shorter ARM in cyclin T1, 
which is also called the Tat-TAR recognition motif (TRM), binds the central loop of TAR. 
Binding of the Tat cyclin T1 complex to both the bulge and loop regions of TAR 
strengthens the affinity of this interaction. All of these components are required for Tat 
transactivation. In the presence of the complex between Tat and P-TEFb, the RNAPII 
elongates efficiently. Because murine CycT1 contains a cysteine at position 261, the 
complex between Tat and murine P-TEFb binds TAR weakly.45 Thus, Tat transactivation 
is severely compromised in murine cells. Cdk9 also must undergo autophosphorylation of 
several serine and threonine residues near its C-terminus to allow productive interactions 
between Tat, P-TEFb, and TAR. Additionally, basal levels of P-TEFb may be low in 
resting cells or only weakly active due to the interaction between P-TEFb and 7SK 
RNA.46 All of these events may contribute to postintegration latency. 
Transcription of the viral genome results in more than a dozen different HIV-specific 
transcripts. Some are processed cotranscriptionally and, in the absence of inhibitory RNA 
sequences (IRS), transported rapidly into the cytoplasm. These multiply spliced transcripts 
encode Nef, Tat, and Rev. Other singly spliced or unspliced viral transcripts remain in the 
nucleus and are relatively stable. These viral transcripts encode the structural, enzymatic, 
and accessory proteins and represent viral genomic RNAs that are needed for the 
assembly of fully infectious virions.  
Incomplete splicing likely results from suboptimal splice donor and acceptor sites in 
viral transcripts. In addition, the regulator of virion gene expression, Rev, may inhibit 
splicing by its interaction with alternate splicing factor/splicing factor 2 (ASF/SF2) and its 
associated p32 protein.47  
Transport of the incompletely spliced viral transcripts to the cytoplasm depends on an 
adequate supply of Rev. Rev is a small shuttling protein that binds a complex RNA stem-
loop termed the Rev response element (RRE), which is located in the env gene. Rev binds 
first with high affinity to a small region of the RRE termed the stem-loop IIB (Figure 6).48 
This binding leads to the multimerization of Rev on the remainder of the RRE. In addition 
to a nuclear localization signal, Rev contains a leucine-rich nuclear export sequence 
(NES). Of note, the study of Rev was the catalyst for the discovery of such NES in many 
cellular proteins and led to identification of the complex formed between CRM1/exportin-
1 and this sequence.49  
The nuclear export of this assembly (viral RNA transcript, Rev, and CRM1/exportin 1) 
depends critically on yet another host factor, RanGTP. Ran is a small guanine nucleotide-
binding protein that switches between GTP- and GDP-bound states. RanGDP is found 
predominantly in the cytoplasm because the GTPase activating protein specific for Ran 
(RanGAP) is expressed in this cellular compartment. Conversely, the Ran nucleotide 
exchange factor, RCC1, which charges Ran with GTP, is expressed predominantly in the 
nucleus. The inverse nucleocytoplasmic gradients of RanGTP and RanGDP produced by 
the subcellular localization of these enzymes likely plays a major role in determining the 
directional transport of proteins into and out of the nucleus. Outbound cargo is only 
effectively loaded onto CRM1/exportin-1 in the presence of RanGTP. However, when the 
complex reaches the cytoplasm, GTP is hydrolyzed to GDP, resulting in release of the 
bound cargo. The opposite relationship regulates the nuclear import by importing  and , 
where nuclear RanGTP stimulates cargo release.51  
For HIV infection to spread, a balance between splicing and transport of viral mRNA 
species must be achieved. If splicing is too efficient, then only the multiply spliced transcripts 
appear in the cytoplasm. Although required, the regulatory proteins encoded by multiply 
spliced transcripts are insufficient to support full viral replication. However, if splicing is 
impaired, adequate synthesis of Tat, Rev, and Nef will not occur. In many non-primate cells, 
HIV transcripts may be overly spliced, effectively preventing viral replication in this hosts.50 
 
  
Figure 6. Late events in the HIV-infected cell culminating in the assembly of new 
infectious virions. 
 
In contrast to Tat and Rev, which act directly on viral RNA structures, Nef modifies the 
environment of the infected cell to optimize viral replication (Figure 6). The absence of Nef in 
infected monkeys and humans is associated with much slower clinical progression to AIDS. 
This virulence caused by Nef appears to be associated with its ability to affect signaling 
cascades, including the activation of T-cell antigen receptor, and to decrease the expression of 
CD4 on the cell surface.51 Nef also promotes the production and release of virions that are 
more infectious.52 Effects of Nef on the PI3-K signaling cascade - which involves the guanine 
nucleotide exchange factor Vav, the small GTPases Cdc42 and Rac1, and p21-activated kinase 
PAK - cause marked changes in the intracellular actin network, promoting lipid raft movement 
and the formation of larger raft structures that have been implicated in T-cell receptor 
signaling.53 Indeed, Nef and viral structural proteins colocalize in lipid rafts.54 Two other HIV 
proteins assist Nef in downregulating expression of CD4.55 The envelope protein gp120 binds 
CD4 in the endoplasmic reticulum, slowing its export to the plasma membrane, and Vpu binds 
the cytoplasmic tail of CD4, promoting recruitment of TrCP and Skp1p (Figure 7). These 
events target CD4  for  ubiquitination  and proteasomal degradation before it reaches the cell 
surface.56  
Nef acts by several mechanisms to impair immunological responses to HIV. In T cells, 
Nef activates the expression of FasL, which induces apoptosis in bystander cells that express 
Fas, thereby killing cytotoxic T 
 
 Figure 7. Late steps in the assembly of new virions. 
 
cells that might otherwise eliminate HIV-1 infected cells. Nef also reduces the expression of 
MHC I determinants on the surface of the infected cell (Figure 6) and so decreases the 
recognition and killing of infected cells by CD8 cytotoxic T cells.58 However, Nef does not 
decrease the expression of HLA-C,59 which prevents recognition and killing of these infected 
cells by natural killer cells.  
Nef also inhibits apoptosis. It binds and inhibits the intermediate apoptosis signal regulating 
kinase-1 (ASK-1) that functions in the Fas and TNFR death signaling pathways and stimulates 
the phosphorylation of Bad leading to its sequestration by 14-3-3 proteins (Figure 6).60 Nef 
also binds the tumor suppressor protein p53, inhibiting another potiential initator of apoptosis. 
Via these different mechanisms, Nef prolongs the life of the infected host cell, thereby 
optimizing viral replication. Other viral proteins also participate in the modification of the 
environment in infected cells. Rev-dependent expression of Vpr induces the arrest of 
proliferating infected cells at the G2/M phase of the cell cycle.61 Since the viral LTR is more 
active during G2, this arrest likely enhances viral gene expression.62 These cell-cycle arresting 
properties involve localized defects in the structure of the nuclear lamina that lead to dynamic, 
DNA-filled herniations that project from the nuclear envelope into the cytoplasm (Figure 6).63 
Intermittently, these herniations rupture, causing the mixing of soluble nuclear and 
cytoplasmic proteins. Either alterations in the lamina structure or the inappropriate mixing of 
cell cycle regulators that are normally sequestered in specific cellular compartments could 
explain the G2 arresting properties of Vpr. 
New viral particles are assembled at the plasma membrane (Figure 7). Each virion consists 
of roughly 1500 molecules of Gag and 100 Gag-Pol polyproteins,64 two copies of the viral 
RNA genome, and Vpr.65 Several proteins participate in the assembly process, including Gag 
polyproteins and Gag-Pol, as well as Nef and Env. A human ATP-binding protein, HP68 
(previously identified as an RNase L inhibitor), likely acts as a molecular chaperone, 
facilitating conformational changes in Gag needed for the assembly of viral capsids.66 In 
primary CD4 T lymphocytes, Vif plays a key but poorly understood role in the assembly of 
infectious virions. In the absence of Vif, normal levels of virus are produced, but these virions 
are noninfectious, displaying arrest at the level of reverse transcription in the subsequent target 
cell. Heterokaryon analyses of cells formed by the fusion of nonpermissive (requiring Vif for 
viral growth) and permissive (supporting growth of Vif-deficient viruses) cells have revealed 
that Vif overcomes the effects of a natural inhibitor of HIV replication.67 Recently this factor, 
initially termed CEM15/APOBEC3G, was identified and shown to share homology with 
APOBEC1, an enzyme involved in RNA editing.68 Whether the intrinsic antiviral activity of 
CEM15 involves such an RNA editing function remains unknown. CEM15 is expressed in 
nonpermissive but not in permissive cells and when introduced alone is sufficient to render 
permissive cells nonpermissive. 
The Gag polyproteins are subject to myristylation, and thus associate preferentially with 
cholesterol- and glycolipid-enriched membrane microdomains 69. Virion budding occurs 
through these specialized regions in the lipid bilayer, yielding virions with cholesterol-rich 
membranes. This lipid composition likely favors release, stability, and fusion of virions with 
the subsequent target cell. 
The budding reaction involves the action of several proteins, including the “late domain” 
sequence (PTAP) present in the p6 portion of Gag (Figure 7).70 The p6 protein also appears to 
be modified by ubiquitination. The product of the tumor suppressor gene 101 (TSG101) binds 
the PTAP motif of p6 Gag and also recognizes ubiquitin through its ubiquitin enzyme 2 
(UEV) domain. The TSG101 protein normally associates with other cellular proteins in the 
vacuolar protein sorting pathway to form the ESCRT-1 complex that selects cargo for 
incorporation into the multivesicular body (MVB).71 The MVB is produced when surface 
patches on late endosomes bud away from the cytoplasm and fuse with lysosomes, releasing 
their contents for degradation within this organelle. In the case of HIV, TSG101 appears to be 
“hijacked” to participate in the budding of virions into the extracellular space away from the 
cytoplasm. 
3 Treatment of AIDS 
 
3.1 Diagnosis 
 
HIV infection was detected by two different ways. The first based on antibody engender by 
immunitary system, (serologic manner) or by the finding of virus molecules and antigenic (virus 
manner). The diagnostic analysis was based on ELISA and Western-Blot tests. 
ELISA is an enzymatic process widely used as screening method thanks to its low costs 
and easy implementation. With this method is possible to find out the antibody versus viral’s 
proteins, for example gp41 e gp120. Sensibility of ELISA test is among 95%, but sometimes 
could be bias answer, called “lie positive” in witch the test result shows positive reply but 
without infection, or “lie negative” in with test result shows negative reply but with infection. 
One of causes of “lie positive” could be the presence of other pathologies that give production 
of different antibody. The “lie negative” for example could happen in persons that take the 
infection very yet. 
The Western Blot (WB) is a more sensible and specific than ELISA test used to confirm 
the result of ELISA test. WB method gives evidence of presence of viral proteins antibody. 
The test’s results are positive when at least two antibodies are found.  
In advance to these tests there are other methods based again on the research of viral 
proteins but not for a diagnostic use but for the screening of infection, in particular during 
HAART therapy. For example HIV-RNA quantity, directly associated to the speed of virus 
replication, give the opportunity to control the effect of the therapy. One of these tests the Q-
PCR (Quantitative Polymerase Chain Reaction) 
 
3.2. Treatment for AIDS  
 
The therapy most effective in the treatment of AIDS is the highly active antiretroviral 
therapy (HAART). This kind of therapy for the treatment of infection by HIV is quite similar 
to chemotherapy against cancer. The efficiency is evaluated by the increasing of the number 
of CD4 cells and by decreasing of blood’s levels of viral RNA. HAART is concerned to use at 
the same time of one or more nucleosidic reverse transcriptase inhibitors, non-nucleosidic 
inhibitors and protease inhibitors. 
With the use of HAART the number of CD4 cells usually increases, and there is a partial 
re-building of immunitary system. In some cases there is no increasing of CD4 cells although 
we can register a suppression of viral replication. In some people, functional improvement is 
associated to a worsening of opportunistic infections due to an increasing of inflammatory 
response to a non physiological level. 
The HAART therapy is recommended to all people who are in an advanced stage of 
infection by HIV. Problems involved with this treatment are about drugs interaction with the 
agents involved in the cure of opportunistic infections, and also problems concerning toxicity 
and tolerability72. 
Compounds that inhibiting viral replication can be divided in some classes: 
a) viral binding inhibitors 
b) virus-cell fusion inhibitors 
c) reverse transcriptase inhibitors 
d) protease inhibitors 
 
To these compounds we can add a possible vaccine that is recently studied as a possible 
therapeutic way. 
 
3.3 Viral binding inhibitors 
 
3.3.1 Soluble derivatives of CD4. 
  
The assumption that the viral glycoprotein gp120 binds to the receptor CD4 protein who 
we can find on the surface of various cells such as T-Helper lymphocytes has suggested the 
production of a soluble derivatives who can get competition whit the cell’s CD4 protein. 
The first problem of these derivatives is the short half-life which has been successfully 
resolved by the linkage of an immunoglobulinic portion and that has demonstrated that these 
compounds are able to inhibit macrophage infection. 
 
3.3.2 Small anionic molecules 
 
Sodic suramine (chart 1) an anionic compound is being used for a long time in the 
treatment of trypanosomiasis and as a potent inhibitor of revers transcriptase of RNA 
carcinogenic virus has now shown active against HIV-1 but it has failed in clinical trials. 
Therefore, there are being considered some of its derivatives belonging to the class of azoic 
colorants like the Blue Evans (chart 1). 
Their character of colorants and the fact that in vivo they were reduced to carcinogenic 
amines has excluded them from the use in mono therapy. 
By the substitution of the diazo- groups whit other moiety who doesn’t create carcinogenic 
groups and by the elimination of electronical conjugations (who assign the colorant propriety) 
there are being synthesized compounds effective in concentration relatively not toxic for the 
host cell. A potent example of this class is the napthalensulfonic derivatives (chart 1) although 
these modifications have conducted to a decreasing in activity. 
 
3.3.3 Polimerics anionics molecules  
 
The dextrans sulphate (chart 1) polisaccharidics molecules esteriphicated whit sulphuric 
acid, cause their in vivo instability and their low oral absorption there were left out. Some new 
compounds have been synthesized and those, to prevent the depolimerization, present a 
hydrocarbon skeleton and to prevent the desolphatation, they present sulfonic acid residues 
instead of sulphuric esters. An example is poly(vinilsulphonic) acid (PVS) (chart 1) who 
interacts whit the protein gp120. 
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  Figure 8: Possibile drug site of action 
 3.4 Fusion inhibitors 
 
The fusion cell-virus depends from the interactions between viral glycoproteins gp120 and 
gp41 and CD4 receptor, a protein that is localized on the surface of various cells. (P.M. 55 
Kd). 
The fusion real mechanism is not been exactly comprised but is widely studied but the 
possibility of inhibiting this bound by molecules such as lectyne, albumine, and triterpen 
derivatives is very interesting. 
A new drug belonging to this class of antiretroviral is the enfuvirtide, synthetic peptide 
formed by 36 amino acidic residues in which the C-terminal portion interacts whit the viral 
membrane glycoprotein gp41 blocking the conformational changes very important for the 
interaction virus-cell. The drug is administered by under skin injection. (chart 2)73. 
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              Figure 9: Possible site of interaction virus-cell  
 
3.5 ReverseTranscriptase Inhibitors  
 
The most important molecules against HIV are these who inhibiting the viral reverse 
transcriptase (RT), a DNA polymerase RNA dependent very important for virus replication. 
3’-azido-2’,3’-Didesossitimidine (zidovudine or AZT)74 (chart 3) who is known active 
against a murine retrovirus, has shown his activity against HIV-1 in vitro . after clinical 
experimentation it becomes the first drug approved by FDA. 
The screening among nucleosidic analogue compounds lead to the discovery of a new 
series of derivatives: 2’,3’-dideoxycitidine (zalcitabine, ddC),75 2’,3’-dideoxyinosine 
(didanosine, ddI),75 3’-deoxy-2’,3’-didehydrothymidine (stavudine, d4T),76 (-)(1S,4R)-4-(2-
amino-6-(cyclopropyamino)9H-purine-9-yl)-2-cyclopentene-1-methanol succinate (abacavir, 
ABC)77 (-)--2’,3’-dideoxy-3’-thiacytidine (lamuvidine, 3TC).78 
These molecules were phosphorilated in position 5’ of sugar ring from selective kinases 
becoming the corresponding triphosphate activated form. Once incorporated into the borning 
nucleic acid, they can’t interact by forming a phospodiesteric bound because they are lacking 
of a hydroxile in position 3’: in such way they act as a chain terminator. 
Considering the highly efficiency demonstrate by these compounds, all the efforts are 
concentrated in the research of acyclic analogues derivatives by phosphonilmethoxialkilic of 
purine and pyrimidines, a class of a wide spread antiviral compounds, who acts as nucleotidic 
inhibitors of RT, which are true drugs because they don’t need bioactivation by 
phosphorylation such as 9-[(R)-2-[[bis[[isopropoxycarbonyl)oxa]fosphynyl]methoxy] 
propyl]adenine, fumarate (1:1) (tenofovir disoproxil, PMPA)  
Among these adeninics derivatives PMEA and PMEDAP are the most active more than 
AZT in a large number of animal models, present an immunomodulatory action and they also 
inhibit other viruses who can infect patients who affected by AIDS. The research extended to 
more than 600 class of drugs has lead to the discover of derivatives 
thetraimidazo[4,5,1,jk][1,4]benzodiazein-2(1H)-onici e –tionici (TIBO) which present a 
potency quite similar to AZT but better selectivity.  
Among benzodiazepinic derivatives, very important is Nevirapine79, Delavirdine80 and 
Efavirenz81 (figure 10)82. These molecules block RT act as a non-competitive inhibitor on an 
allosteric site of the enzyme, the Non-Nucleosidic Binding Site (NNBS).  
Because of their activity is strictly connected to the enzyme structure, gene mutations 
induce resistance against these classes of compounds; but at the same time the selectivity 
against HIV-1’s RT is very important. 
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Table 1. Anti-HIV Food  & Drug Administration (FDA) approved drugs. 
 
Nucleosidic and Nucleotidic inhibitors of  RT (NRTIs, NtRTI) 
Year Name 
Commercial 
Name 
Producer 
 
1987 
 
Zidovudine 
 
Retrovir® 
 
GlaxoSmithKline 
1991 Didanosine 
Videx® 
Videx EC® 
Bristol - Myers Squibb Co 
1992 Zalcitabine Hivid® Roche Laboratories 
1994 Stavudine Zerit® Bristol - Myers Squibb Co 
1995 Lamivudine Epivir® GlaxoSmithKline 
1997 Lamivudine/Zidovudine Combivir® GlaxoSmithKline 
1998 Abacavir Ziagen® GlaxoSmithKline 
2000 Abacavir /Lamivudine/Zidovudine  Trizivir® GlaxoSmithKline 
2001 Tenofovir Viread® Gilead Sciences Inc 
2003 Emcitrabine Emtriva™ Gilead Sciences Inc 
2004 Abacavir/Lamivudine Epzicom® GlaxoSmithKline 
Nucleosidic and Nucleotidic inhibitors of  RT (NRTIs, NtRTI) 
Year Name 
Commercial 
Name 
Producer 
2004 Emcitrabine/Tenofovir Truvada® Gilead Sciences Inc 
 
non nucleosidic RT inhibitors (NNRTIs) 
Year Name 
Commercial 
Name 
Producer 
 
1996 
 
Nevirapine 
 
Viramune® 
 
Boehringer Ingelheim 
Pharmaceuticals Inc 
1997 Delavirdine Rescriptor® Pfizer Inc 
1998 Efavirenz Sustiva® Bristol - Myers Squibb Co 
 
 Protease inhibitors (PIs) 
Year Name 
Commercial 
Name 
Producer 
 
1995 
 
Saquinavir 
 
Invirase® 
 
Roche Laboratories 
1996 Ritonavir Norvir® Abbott Laboratories 
1996 Indinavir Crixivan® Merck & Company, Inc 
1997 Nelfinavir Viracept® Agouron Pharmaceuticals Inc 
1997 Saquinavir Fortovase® Roche Laboratories 
1999 Amprenavir Agenerase® Vertex Pharmaceuticals Inc 
2000 Lopinavir/Ritonavir Kaletra® Abbott Laboratories 
2003 Atazanavir Reyataz™ Bristol - Myers Squibb Co 
2003 Fosamprenavir Lexiva™ GlaxoSmithKline 
 
Fusion inhibitors (FIs) 
Year Name 
Commercial 
Name 
Producer 
 
2003 
 
Enfuvirtide 
 
Fuzeon™ 
 
Roche Laboratories 
 
          Figure 10: Possibile drug site of action of RT’s inhibitors  
3.6 Protease inhibitors  
 
The HIV-1 protease belongs to the family of aspartilprotease and is an enzyme that plays a 
relevant role in a post integrational phase (figure 11), before and during viral gemmation. At 
this level the retroviral protease cuts the poliprotein gp160, viral precursor, in proteins that 
can creates the mature virion there are more evidences that the protease can attack some 
host’s proteins.The active site of this enzyme is formed by the three-peptide aspartic acid- 
threonine- glycine that is a typical sequence of the central core of some aspartic proteases. 
There were prepared and tested many compounds which structure was miming the sequence 
of three-peptide asparagines-phenilalanine-proline. Compounds such as Ampenavir84, 
Atazanavir85, Fosamprenavir86, Indinavir86, Lopinavir87, Nelfinavir88, Ritonavir89, and 
Saquinavir90 (chart 5) show a good anti-protease activity, but problems involved in ADME 
limit their use. 
 
                 Figure 11: Possibile drug site of action of Protease’s inhibitors 
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3.7 Anti-HIV-1 Vaccine 
 
The needle to develop a vaccine for therapeutic scope or preventive is now very evident.  
An efficient vaccine that can limit or prevent the diffusion of the infection is very far to be 
discovered because of many factors. 
Virus shows in vivo a great variability, in fact there were isolated more than 100 variants 
of HIV-1. Mutations in one only amino acid in the variable region of envelope give to the 
virus the capability to survive into the body and to avoid the immunitary system defences.  
The phenomenon of enhancing antibodies, instead to play a neutralizing effect on virus, 
play a role in the entrance in macrophages cells by the Fc fragment of Ig. Particularly the 
vaccine’s studies are point out to obtain a recombinant protein subunit. Because of their highly 
dangerousness vaccine based on inactive viruses are not used. 
Actually, research is concentrate in the variable region of gp120, but very important are 
the results by the PCR studies. This method has lead to identify a high conserved sequence of 
gp120 against which was obtained a higher antibodies response. 
There are so synthesized some peptides with the same sequence with the aim to obtain a T 
Helper reply with production of IL-2. 
4. 3-D QSAR: an introduction 
 
In Drug Discovery, synthesis, biological evaluation and screening of hundred and 
thousand of potential drug candidates is an extremely expensive and laborious procedure, 
more efficient strategy are necessaries. A rational mode is the derivation of structure-activity 
hypothesis and their quantitative evaluation without biological assay or laboratory synthesis.  
However, in doing so, it is important to better understand the aim and the limitations of the 
applied approach in order to use it in appropriate and correct manner.  
The important computers contribution to science is their capability to quantify and 
evaluate hypotheses much faster. 
With the availability of powerful workstation, molecular modeling and drugs three 
dimensional quantitative activity relationships (3-D QSAR) their interaction complexes 
became increasingly important. 
Major contribution to 3D QSAR method development were Hansch-Dieter Höltie’s 
calculation of interaction energies in hypothetical drug receptor complexes92, Garland 
Marshall’s active analogues approach92, Peter Goodford’s program GRID93 and Richard 
Cramer’s comparative molecule fields analysis (CoMFA)94. In parallel, powerful statistical 
tools as Partial Least Square (PLS)95 analysis and Gabriele Cruciani’s software GOLPE96, had 
to be developed to correlate a large number of data points with the biological activity values of 
a limited number of objects. 
 
4.1 Partial Least squares 
 
Partial least squares (PLS) is a general a powerful tool for deriving multi linear 
relationships among columns of data. Compared to classical approaches to the same problem, 
notably multiple regression, PLS has been show to be the much less susceptible to change 
correlation, that is, reporting as scientific fact random pattern among data values that are 
unrelated. PLS may also be applied to a much wider range of problems, from simple 
traditional least-squares Y versus X line fitting to the COMFA approach of fitting thousand of 
columns descriptor of molecular characteristics to same biological property. PLS result are 
evaluated for their ability to predict new information, using cross validation Most often PLS is 
performed in two stages: the first with cross validation to determine how rich or complex a 
model is appropriate for the data values (how many components to use), the second without 
cross validation and the optimum number of components establish the single model which 
best represent the data. 
Nowadays PLS represent a new mathematical approach to analyze a great number of 
descriptors and to create a correlation between them and biological activity (as in my model) 
or a different characteristic. For example this type of analysis was use in cosmetic or 
alimentary industry to obtain an equation that represents a particular product (wines, cheeses 
and creams). 
PLS can be interpreted in many ways: conceptually, mathematically etc. In this contest the 
most important thing is that PLS finds combination of the structural descriptors that a) well 
predict biological activity and b) well model the structure descriptor matrix. 
Mathematically summarize the X-variables in a few orthogonal new variables called 
scores, or latent variable (LVs). The score vectors are collected in a matrix T (N= number of 
object) (N x A).This summary is achieved by means of a projection of X on an A-dimensional 
plane. The coordinates of each object into this plane are the score. 
If there is more than one Y-variable, PLS simultaneously summarize the Y-data model. 
PLS proceeds by calculating one component (model dimension) at a time and one-stop when 
cross-validation becomes significant. The score vector (T) are then used as new predictor 
variables to model Y. Since the score are few and orthogonal, and for this reasons independent 
there aren’t problem of spurious correlations. In practice PLS give us a function without bias 
correlation between Y and T  Y= f(T) 
 
4.2 The history and use of Quantitative Structure Activity 
Relationships (QSAR). 
More than century years ago, in 1893 Charles Richet published a note on the relationship 
between the toxicity and the physicochemical properties of a series of organic compounds. 
From this analysis Richet concluded that: more soluble was less toxic97. In the same year Emil 
Fisher investigate the influence of - and - configurations of different glycosides on their 
enzymatic cleavage formulating that enzyme and glycoside must fit together as lock and key, 
in order to obtain different effect on each one98. Only fifty years later Paul Ehrlich’ 
investigation on anti-bacterial dyestuffs led to the concept of receptor.99.These fundamental 
theory stimulating chemical researcher and more attention was attributed to the effect of 
pharmacophoric groups on selectivity and activity. The situation changed in 1964 when 
Hansch and Fujuta100) published their studies on quantitative relationship between 
physicochemical properties and biological activities and Free and Wilson developed a model 
of additive group contribution to biological activity values101 However the three-dimensional 
structures of molecules not be considered in these approaches. 
Hansch analysis is a relatively easy method. It assumed that all series compounds interact 
with their biological target, be it an enzyme, a nucleic acid or a channel protein, in the same 
manner and with the identical conformation. The situation is more complex in 3-D QSAR 
analysis where the series of compounds are often dissimilar, alignment can introduces bias 
and structure of biological receptor are not available. Therefore Hansch analysis guided to the 
development of 3-D QSAR, prior to 1979 no general concept was developed how to 
implement 3-D features in a QSAR analysis. In 1988 R. Cramer, introduced 3-D QSAR 
involving the analysis of the quantitative relationship between the biological activity of a set 
of compounds and their three-dimensional properties using statistical correlation methods102  
From the very first formulation of a lattice model to compare molecules by alignment 
them in 3D space and by mapping their molecular fields a 3-D grid, it took nearly a decade 
until CoMFA103 and commercial software 104-105 were developed.  
The success of a QSAR development is based on three fundaments: the biological data, the 
selection of compounds and the selection of structural descriptors. The selection and 
calculation of structural descriptors plays a crucial role in the ability of resulting model. Any 
mathematical modeling needs homogeneity of the variables, each X and Y variable, must 
mean the same thing for all objects (molecules). This necessitates some kind of alignment of 
the compounds. Also important is to note that is not necessary to map all molecule structure 
but only changing moiety. A constant backbone or large fragment does not contribute any 
information and hence no parameterizations. The selection of compounds for the learning set 
of the QSAR is equally important. It must be remember, however, that an unbalanced and 
unrepresentative selection of compounds will always yield a low quality QSAR, difficult to 
interpret and perhaps misleading prediction.  
 
4.2.1 Design 
 
When we developing a QSAR model we are investigating direction in an abstract 
multidimensional structure space, and how activity changes when we move in these different 
direction. This structure space has one axis for each possible structural factor that can be 
changed in our investigated molecules. The variation along each axis in bounded by a lowest 
and highest possible value: in a peptide, for instance, we cannot have amino acid smaller than 
glycine or larger than tryptophan. To be able to investigate well all directions in the space, we 
need a set of compounds that well spans this space. 
 
4.2.2 Missing Data 
 
Although data analysis works better when the data are complete, PLS modeling tolerate 
moderate amounts of missing data both in X and in Y, provided that the missing elements are 
fairly randomly spread out over all objects and variables. A reasonable percentage is 10% 
maximum missing data in X and Y. Naturally, Y must be multivariate for PLS to tolerate 
missing data in Y. Presently no working method exist for the proper analysis of such data. The 
better result could be obtained using a combined analysis of two partial data set; one with all 
molecules (object) and only screening Y-values, and a second with just the highly active 
compounds and all Y-variables. The latter may give information about the correlation pattern 
between the various tests that might be used to interpret the first “rich” model with respect to 
more interesting high-cost Y-variables. 
 
4.2.3. Scaling  
 
The result of PLS and PCA projection depend of the scaling of the data. Using an 
appropriate scaling of the data, one can focus the model on more important Y-variables, and 
use experience and fundamental knowledge to increase the weights of X containing much 
information and decrease the weights of other parts containing little information. 
 
4.2.4. Data analysis and model interpretation 
 
With PLS one needs to estimate also the model complexity: for example the number of 
significant PLS components (model dimension A). Particularly with the large number of X-
variables, it is essential to strictly test the meaning of each models dimension to obtain that the 
final model include only significant components. This is fundamental to limit overfit and to 
give validity to the model. Cross-Validation provides a very reliable way for testing this 
significance. 
With CV one estimates the predictive ability of the model by: 
1- calculating an ensemble of modes from reduced data where parts of the 
original data have been deleted, and then 
2- 2- using each model to predict the data the where deleted from its modeling 
calculation. 
These deletion and calculation are made in such a way that each object is deleted once and 
once only over the model ensemble. One then computes the sum of all objects of squared 
differences between predicted (by the model without the deleted object) and experimental Y-
value. This sum is called r2. Moreover the CV result is expressed also by SDEP. 
Sometimes CV of PLS indicates that the first or second dimension is insignificant while 
there are one or several significant model dimensions beyond these. Hence, if only a small 
part of Y has been explained, one should look also at the model dimension after the apparently 
insignificant one, and continue the modeling if this is indicated to be significant by CV. This 
is completely safe as long as the number of model dimension.  
Conceptually, we can see the scores as estimates of same molecules characteristics. 
Hence one should make efforts to understand and interpret these scores, witch is best done 
by considering plots and their patterns. Each score vector is a linear combination of the X-
variables with a coefficient wa. Similarly, the Y-score is linear combinations of the Y-
variables with another coefficient ta. Hence the size of element of wa informs about the 
importance of that variable. For example is possible to find out that a second score vector is 
composed mainly of hydrophilic descriptors, and also witch part of molecules contribute 
much. With the 3 D-QSAR color coded plots of coefficients are informative in this respect, 
making interpretation easier. 
Because PLS is a projection method outlier and other inhomogeneities are easily detected. 
Once the 3-D QSAR model has been developed based on the training set of compounds, it 
can be used to predict the activity profile Ypred of new, not yet synthesized molecules. This 
prediction is done by first translating the structure of a new compound into a vector of 
structure descriptor values. This vector is trans-formed and scaled in the same way of training 
set data. Thereafter the resulting vector is inserted into the QSAR model giving predicted 
values of Y-variable. Usually a test set is used to evaluate the prediction ability of the model 
and to evaluate the standard error of prediction. Also is important to evaluate the structurally 
similar among data set and prediction set. If this similar characteristic is greater then a value 
prediction is unreliable. 
 
4.2.5. QSAR Plots 
 
The QSAR-PLS model provides two kinds of plots: score plots showing the objects (here 
molecules), and loading/weight plots showing the variables of X and/or Y. Plotting the Y-
scores versus the corresponding X-score shows the connection between structure (X) and 
activity (Y). 
The use of PLS for 3 D- QSAR model and data analysis is very advantageous. 
 
4.3 Application of GOLPE 
 
The use of GOLPE software allows the developing of 3-D QSAR model implementing 
PLS technique previously analyzed and to obtain plot representation of it. Obtained the 3D 
descriptor by the GRID the GOLPE procedure is given by the following steps:  
 A variable selection phase aimed at deleting redundancy 
 Evaluations of the effects of each individual variable on the predictive power 
of the model, obtained by the comparison with the apparent effect of dummy variables on a 
representative number of variable combinations 
 Evaluation of the predictive power of the supposed optimal equation. 
Hence, the reference method uses a PLS implementation in which the validation is made 
in leave-one-out and which does not include any variable selection. Consequently, it seems 
appropriate to consider GOLPE a culturally advance tool which gives better reliability in 
terms of prediction. 
The predictive power of the model can be evaluated by the SDEP parameter computed by 
GOLPE both in term of self-consistency or on a validation set. Although this latter approach 
gives results dependent upon the selection of the test set, it seems, whenever possible, more 
reliable. Nevertheless, it is very fast in computation. 
GOLPE seems to be a powerful tool to improve the quality of the result of the regression 
step (PLS) of any 3 D-QSAR models. 
Data pretreatment is very important in effect different data pretreatment generate different 
PLS models and consequently, different results, both in terms of predictive power and in term 
of interpretation. An appropriate data pretreatment should take into account, the fact that 
interactions relevant to the ligand receptor binding can occur only in the area of the molecule 
surface, but, on the other hand, all grid point should in principle be given the same opportunity 
of showing up as important. Another critical point is the cut-off value to be used on fields or 
energies. In order to avoid chemometric model depending too heavily on points of high 
leverage it is appropriate that these range are roughly centered. 
A series of crystallized and modeled data set were used and studied to establish if is more 
useful or not to autoscaling variables scores and after or before data agreement between 
predicted and experimental region of interaction is obtained on preselecting variables and 
autoscaling the remaining.  
GOLPE plots makes models interpretation easer but is important to take in to account that 
when transforming the PLS loading into the pseudo coefficient of the polynomial in the 
original variables, it is not appropriate to give too much credit to the individual coefficient: 
they suffer of the same instability of Multi Linear Regression, although prediction are stable 
since they are derived by PLS.  
 
 
 
 
5. Design of Indolyl Aryl Sulphones (IASs) 
 
5.1 Towards the design of new Indolyl Aryl Sulphones 
While searching for new anti-AIDS agents, we focused our attention on Nitrophenyl 
Phenyl Sulphones (NPPS, compound 1)106, a new class of NNRTIs discovered at the National 
Cancer Institute (NCI) during a large-scale drug-screening program. The most active 
compound, the dinitro derivative 2 (EC50 0.89 μM), was discarded due to its poor 
bioavailability, while the (4-methoxy-2- nitrophenyl)phenylsulphone 3 (EC50 3.4 μM) was 
selected for further studies. In our laboratories we selected 107 NPPS 1 (Chart 6) as lead 
compound for the design of new isosteres characterized by the presence of a pyrrole nucleus. 
The new Pyrryl Aryl Sulphones (PASs) were less potent than NPPS, although they were also 
less cytotoxic (PAS 4, EC50 15.08 μM, CC50 = >308 μM). Extensive SARs studies led to 
disclose new PAS derivatives active at submicromolar concentration characterized by the 
para-chloroaniline moiety as a featuring pharmacophoric group 108-109 (PAS 5, EC50 0.18 μM). 
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Chart 6 
 
Considering the tricyclic structure of known NNRTIs suh as NVP and TIBO 110-111 (6)112-
113, the PAS derivatives were intramolecuraly cyclized to obtain new pyrrolo[1,2 
b][1,2,5]benzothiadiazepine (PBTDs), and some related pyrrolo[2,3-b][1,5]benzothiazepine 
and pyrrolo[3,2-b][1,5]benzothiazepine derivatives (general structures 7-9) 114-115 (Chart 7). 
PBTDs derivatives showed submicromolar anti-HIV activity, comparable to that of NVP 
(10b: EC50 = 0.5 μM; CC50 = > ≥ 300 μM). 
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Chart 7 
 
In 1993 Merck Research Laboratories reported the anti-HIV-1 activity of the potent RT 
inhibitor L-737,126 (11, EC50 0.001 μM, CC50 = 200 μM)108 (Chart 8). Similarly to the PAS ➔ 
PBTD transformation, Silvestri et al. 155 synthesized two series of 11's analogues. 
Representative examples are the conformationally constrained 2-chloro-5H-indolo[3,2-
b][1,5]benzothiazepi-6(7H)-one 12,12-dioxide (12) and the acyclic variant 3-[(2-amino-5-
chlorophenyl)sulphonyl]-5-chloroindolo-2-carboxamide (13) (Chart 3)155. Unfortunately both 
12 and 13 related series were less active than reference compound 11. These results pulsed us 
to do molecular modelling studies to rationalize the experimental data. Docking studies 155 of 
11, 12 and 13 revealed different binding mode for each molecule: the compounds docked into 
the NNBS of RT showed dissimilar orientations of the bound conformations (Figure 12). 
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Chart 8.  
 
As reported by Silvestri et al. 116the different binding modes of compounds 12 and 13 
would account for non-parallel SARs of PBTDs and their related PASs derivatives. Using the 
three-dimensional structure of RT complexed with Cl2-α-APA (14) 117(Chart 9) and 5's X-ray 
structure (Figure 12A), a model of RT/5 complex was derived 118-119 (Figure 12B). This model 
was used to design new PASs derivatives and some related analogues (Chart 9). 
 A B C 
Figure 12. Molecular models of L-737,126 (A), 13 (B) and 12 (C) docked into the non-
nucleoside binding site of RT. Hydrogen bonds are highlighted by dashed lines. 
 
Among these compounds, derivative 15 (Chart 9) was found the most active (EC50 0.045 
μM, IC50 0.05 μM and CC50 240 μM). Compared with those of lead compound 5, these values 
represented significant improvements in the cell-based and enzyme assays. Molecular docking 
studies led to design new derivatives 16, 17 and 18 (Chart 9) based on the hypothesis that 
additional hydrogen bond(s) would favour the binding of the inhibitors into the NNBS (Figure 
13). Although compounds 16-18 were found inactive in cell-based assay, they inhibited the 
RT enzyme at micromolar concentrations (16: IC50 2 μM; 17: IC50 3 μM; 18: IC50 = 9 μM).  
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Chart 9.  
 
  
A B 
Figure 13. (A) Crystal structure of compound 5 showing the thermal ellipsoids at 
40% probability and the labelling of non-H atoms. (B) Derivative 5 (yellow) docked 
into the RT NNBS. Only a subset of residues closest to the ligand is displayed for 
sake of clarity.  
 
Docking studies of compound 11 revealed positive attractive π-π interactions between the 
phenyl ring and an aromatic rich pocket formed by Tyr188, Tyr188 and Trp229. These 
findings prompted us to design and synthesize 1- and 3-arylsulphonyl-5-chloroindoles (for 
example compounds 18a-d and 19a-e) (Chart 10) 108,120  
 
  
A B 
Figure 13 to be continued 
 
C 
Figure 13. (A) Theoretical model of the RT/16 complex. Two hydrogen bonds are 
hypothesized to occur between the ureidic NH groups of the docked molecule and 
the carbonyl oxygen’s of Lys101 and His235. Only a subset of residues of the non-
nucleoside binding site closest to the ligand is displayed. For comparison in (B) is 
reported the theoretical model of the RT/5 maintaining the same orientation as in 
(A). In (C) is reported the theoretical model of the RT/17 complex. Two tautomeric 
forms of the benzimidazole derivative 17 were considered differing in the position 
of the NH group. This latter donates a hydrogen bond to the carbonyl oxygen of 
Lys101 (tautomer on the left) or His235 (tautomer on the right). Only residues 
Lys101 and His 235 of the NNBS are displayed.  
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19c: R = 4-Me (EC50 = 0.003 M)
19d: R = 2,4-Me2 (EC50 = 0.004 M)
19e: R = 3,5-Me2 (EC50 = 0.004 M)
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Chart 10 
 
5.2 IASs: the use of molecular modelling techniques to design new and 
improved anti-HIV derivatives  
 
5.2.1 The first development 
The indol-1-yl aryl sulphones were found poorly active or inactive against HIV-1. In 
contrast, the indol-3-yl aryl sulphone series showed highly activity both in cell-based and in 
enzyme assays.110. SAR analysis showed that both the carboxamide function and the methyl 
substituents on the 3-phenyl ring were crucial for the high activity and selectivity of 
derivatives 19a-e (Chart 10). These compounds showed EC50 values comparable to that of 
reference compound 11 against HIV-1 WT. Compounds 19a-e were also active 110 against the 
most common and clinically relevant HIV-1 drug-resistant mutant strains at concentrations 
comparable to that of EFV.  
 
5.2.2 Combining SBDD (docking) and LBDD (3-D QSAR) Studies  
To better understand the SAR of the synthesized IASs, extensive docking and 3-D QSAR 
studies were undertaken. The Autodock3 program 121 proved to be a valid tool in structure 
based drug design (SBDD) 122-123 that, in some extent in cross-docking experiments using 40 
different experimentally determined co-crystallized RTs conformations124 was also able to 
include the induced fit. Therefore Autodock3 was used for all IASs’ docking studies. For the 
ligand-based drug design (LBDD) approach, the GRID/GOLPE 125 combination was adopted.  
6. Molecular Modeling on Indolyl Aryl Sulphones (IASs) 
 
6.1 Docking Studies  
The first utilized approach has the aim to explain binding mode of most active derivative 
11. It was analyzed by means of a cross-docking procedure using fourteen experimentally 
determined 3-D structures of WT RTs (pdb codes 1dtq,126 1dtt,126 1eet,127 1fk9,128 1hni,129 
1hnv,130 1jlq,131 1rt1,132 1rt2,132 1rt3,133 1rt4,134 1rt5,135 1rt7,135 1vrt,136 and 1vru,130)137 In all 
cases the docked conformations were in good agreement with each other. Only the 
carboxamide function displayed some uncertainty because it was oriented to the same side of 
indole NH or rotated about 180° (Figure 14, Chart 11).  
The binding conformation of compound 11 proposed by docking studies, was characterized 
by four different distinct interactions (Figure 14): (i) an hydrogen bond between the indole 
NH or the carboxyamide NH with the Lys101 carbonyl oxygen (blue residue in Figure 15); 
(ii) a π-π hydrophobic interaction between the phenyl ring and an hydrophobic aromatic-rich 
pocket formed mainly by the side chains of Tyr181, Tyr188, Phe227 and Tyr229 (red surface 
in Figure 15); (iii) a purely hydrophobic interaction between the sulphonyl group and α, β 
carbons of Val106, Val179 and the Lys103 side chains that describe a small pocket into the 
NNBS (yellow surface in Figure 15); (iv) the indole chlorine atom was found to make 
selective positive contacts with Pro236 .(magenta residue in Figure 15) 
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Chart 11. (A) The carboxamide function is in cis position with respect to the indole 
NH. The amide NH2 forms a hydrogen bond with the carbonyl of Lys101. (B) The 
carboxamide is in trans position. A hydrogen bond is formed between the indole NH 
and the carbonyl of Lys101. 
 
 Figure 14 Graphical result of the dockings of reference compound 11 into  
fourteen NNBSs. Conformations docked in the different NNBS are colour coded; 
 in the legend are reported the PDB entry codes of the used RTs. A sketch of the 
NNBS sub pockets is also reported 
 
 
 Figure 15. Binding mode of 11 (atom type colour). in red the hydrophobic pocket formed 
by Tyr181, Tyr188, Phe227 and Trp229 that accommodate the benzene moiety; in yellow 
the small hydrophobic cleft formed by Val106, Val179 and α, β carbons of Lys103 side 
chain that accommodate the sulphone group. In cyan are represented the H-bonds between 
11 and Lys101 (blue). In magenta is depicted the Pro236 residue. 4Å RT NNBS are also 
reported (black line) for clarity. 
 
To validate the docking procedure, parallel docking and cross-docking studies were 
conducted on all the complexes of the ligand co-crystallized within the NNBS of the 14 RTs. 
Autodock3 was able to reproduce with a minimal error the experimental binding mode of all 
the ligands.124 
 
6.2  3-D QSAR Studies  
The above docking procedure was coupled with three-dimensional structure-activity 
relationship (3-D QSAR) techniques with the aim to develop useful descriptive models for the 
design of new IASs. The synthesis of new derivatives would prioritise activity predictions.  
 
6.2.1 Definition of the first 3-D QSAR model  
A training set of 70 molecules (Table 2), compiled using fifty indol-3-yl and twenty indol-
1-yl aryl sulphones, was used to develop a predictive model 137. Both active and inactive 
compounds were included to better analyze favourable and unfavourable ligand/receptor 
interactions. Moreover, the inactive derivatives proved to be necessary in order to code, in the 
model, those information (as grid variables) needed to discriminate active versus inactive 
compounds. Using the 3-D coordinates of the RT extracted from the complex with the IASs 
related di-aryl sulphone 739W94 131 (Figure 16) the training set molecules were structure-
based aligned by a docking procedure into NNBS. In several cases, different binding modes 
were found among the conformations suggested by the Autodock3 program. Since the 
molecular alignment of the training set is a crucial step in a 3-D QSAR, two different 
alignment rules were used: the lowest energy docked conformations of the most populated 
clusters (“best cluster alignment”), and the first ranked docked conformations as obtained 
from the Autodock3 run (“best docked alignment”). 
  
 
 
 
 
 
 
 
 
 
Table 2. Structure and anti-HIV-1 activities of Training Set 
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A B 
Compd structure X Y Z R 
wtIIIB 
EC50 (μM) 
11 A SO2 NH2 Cl H 0.001 
20 A S OEt H H 1.4 
21 A S OEt H 2-NH2 >200 
22 A S OEt H 2-NH2-5-Cl ≥200 
23 A S OEt Cl 2-NH2 2.3 
24 A S OEt Cl 2-NH2-5-Cl 2.5 
25 A SO2 OEt H H 3.7 
26 A SO2 OEt Cl 2-NH2 >200 
26 A SO2 OEt H 2-NH2-5-Cl 2.5 
28 A SO2 OEt Cl 2-NH2-,5-Cl 1.9 
29 A S NH2 H H 1.4 
30 A S NH2 H 2-NH2-5-Cl 9 
31 A S NH2 Cl H 0.02 
32 A S NH2 Cl 2-Me 0.3 
33 A S NH2 Cl 4-Me >0.45 
34 A S NH2 Cl 4-F 1.4 
35 A S NH2 Cl 4-Cl 3.1 
Compd structure X Y Z R 
wtIIIB 
EC50 (μM) 
       
36 A S NH2 Cl 4-iso-Pr 1.9 
37 A S NH2 Cl 4-tert-Bu 8 
38 A S NH2 Cl 3,5-Me2 0.006 
39 A S NH2 Cl 2,6-Cl2 1.2 
40 A S NH2 Cl 2-NH2-5-Cl 1.2 
41 A SO2 NH2 H H 0.18 
42 A SO2 NH2 H 2-NH2-5-Cl 0.3 
19a A SO2 NH2 Cl 2-Me 0.001 
19b A SO2 NH2 Cl 3-Me 0.001 
19c A SO2 NH2 Cl 4-Me 0.003 
43 A SO2 NH2 Cl 4-F 0.014 
44 A SO2 NH2 Cl 4-Cl 0.011 
45 A SO2 NH2 Cl 4-iso-Pr 0.08 
46 A SO2 NH2 Cl 4-tert-Bu 0.13 
19d A SO2 NH2 Cl 2,4-Me2 0.004 
19e A SO2 NHy Cl 3,5-Me2 0.001 
47 A SO2 NH2 Cl 2,6-Cl2 0.1 
48 A SO2 NH2 Cl 2-NH2-5-Cl 0.04 
49 A SO2 NH2 Br 3,5-Me2 0.002 
50 A SO2 NHy COMe 3,5-Me2 0.015 
51 A SO2 NH2 CH(OH)Me 3,5-Me2 0.025 
52 A S NHNH2 Cl H 0.55 
53 A S NHNH2 Cl 4-Me 1.5 
54 A S NHNH2 Cl 4-F 5 
55 A S NHNH2 Cl 4-Cl 10 
56 A S NHNH2 Cl 2-NH2-5-Cl >13 
57 A SO2 NHNH2 H H 0.53 
58 A SO2 NHNH2 Cl H 0.01 
59 A SO2 NHNH2 Cl 4-Me 0.05 
60 A SO2 NHNH2 Cl 4-F 0.32 
61 A SO2 NHNH2 Cl 4-Cl 0.19 
Compd structure X Y Z R 
wtIIIB 
EC50 (μM) 
       
62 A SO2 NHNH2 Cl 3,5-Me2 0.13 
63 A SO2 NHNH2 Cl 2-NH2-5-Cl 0.3 
64 B SO2 H H H >150 
65 B SO2 COOEt H 4-Cl >100 
66 B SO2 COOEt H 2-NO2 1.8 
67 B SO2 COOEt H 2-NO2-5-Cl >100 
68 B SO2 COOEt H 2-NH2-5-Cl 1.8 
69 B SO2 H 3-COOEt H >32 
70 B SO2 H 3-COO-iso-Pr H >54 
71 B SO2 H 5-Cl H >75 
72 B SO2 COOEt 5-Cl H >200 
73 B SO2 COOEt 5-Cl 4-Me >200 
74 B SO2 COOEt 5-Cl 4-Cl >200 
75 B SO2 COOEt 5-Cl 2-NO2-5-Cl >31 
76 B SO2 COOEt 5-Cl 2-NH2-5-Cl 8.3 
77 B SO2 H 5-Cl,3-COOEt H >42 
78 B SO2 H 5-Cl,3-COO-iso-Pr H >200 
79 B SO2 CONH2 H H 15 
80 B SO2 CONHNH2 H H >200 
81 B SO2 CONH2 5-Cl H 66.6 
82 B SO2 H 3-CONH2 H >32 
83 B SO2 H 5-Cl,3-CONH2 H ≥200 
 
Table 2. Structures and anti-HIV-1 activities of compounds used as the 3-D QSAR training 
set.  
 
 Figure 16. Structure of 739W94 (left). Superimposition of the experimental 
conformation found in the 739W94/RT with the docked pose of 90 (right). 
 
On the aligned molecules, the molecular interaction fields (MIF) were calculated by the 
GRID software 93 using either the aromatic carbon (C1) or water (OH2) as probes, alone and 
in combination. 
The MIFs of the training set were imported in GOLPE along with the inverse of the 
logarithm of the experimental anti-HIV-1 activities (pEC50s). It could be argued that cell-
based activities would not be suitable for such a 3-D QSAR study, enzyme-based assays 
(IC50s) being a more appropriate choice. Nevertheless, it has been proved that there is a good 
correlation between enzyme-based (IC50) and cell-based (EC50) assays, and therefore, data 
derived from cell-based activities were expected not to affect the 3-D QSAR. 
By combining two different alignment strategies (best docked or best cluster docked 
conformation) and three probes arrangements (C1, OH2 and C1+OH2), six 3-D QSAR 
models were developed by means of the PLS algorithm implemented in the GOLPE 
program92. After data pretreatment, the smart region definition (SRD) was used in the 
fractional factorial design (FFD) variable selection138. The FFD selections were continued 
until no further statistical improvements were observed. To measure the goodness of the 
model, the statistical indices r2, q2, and SDEP were employed. The six final 3-D QSAR 
models were characterized by correlation coefficient (r2), predictive correlation coefficient 
(q2), and cross-validated standard deviation of errors of prediction (SDEPCV) values falling in 
the ranges 0.79-0.93, 0.59-0.84, and 0.69-1.07, respectively (Table 3). For both the FFD 
selections and the cross-validations, the group method was used, setting to five the number of 
groups to be used.  
Table 3. Statistical results of the 3-D QSAR models 
 
Model Alignment Grid probes varsa PCb r2 q2 SDEPCV 
1 best cluster C1= 665 3 0.88 0.72 0.88 
2 best docked C1= 683 3 0.93 0.84 0.69 
3 best cluster OH2 752 2 0.85 0.68 0.95 
4 best docked OH2 669 3 0.92 0.81 0.74 
5 best cluster C1= and OH2 1140 2 0.79 0.59 1.07 
6 best docked C1= and OH2 709 3 0.91 0.79 0.76 
Table 3  aNumber of selected variables. bNumber of principal components which showed 
maximum q2 value. 
 
As the six 3-D QSAR models were endowed of similar statistical profiles, an external test 
set (compounds 334-341) taken from a previously reported series of indolyl aryl sulfones was 
used to measure their predictive ability (Table 4). On the basis of the standard deviation error 
of prediction value on the test set (SDEPTest-Set), the external validation proved the best cluster 
alignment/OH2 GRID probe combination (model 3, SDEPTest-Set = 0.88, Figure 17) as the 
most predictive. Selected for description of the 3-D QSAR maps and it was chosen as a tool 
for design and prediction of pEC50s of new IAS derivatives. Apart from the optimal 
combination between the alignment and the probe choice, the higher predictive ability of 
model 3 can also be attributed to the fact that the model is defined with two principal 
components (PC) only. In fact, it seems that the extraction of a further PC (models 1, 2, 4, and 
5) enhances the self-consistency (cross-validation) of the model, but less predictive 3-D 
QSAR are obtained (Table 4). 
 
 
6.2.2 Model interpretation 
3-D QSAR models are built with the aim to predict the biological activity of new untested 
compounds139. The prediction ability of the 3-D QSAR model depends on the PLS 
coefficients associated to each variable. The regression PLS coefficients 164 are useful for the 
interpretation of the PLS model and for predictions of external objects (test set). In order to 
interpret the model, the PLS coefficients are plotted as contour plots (or polyhedrons) 
connecting grid points with similar values. 
 
yE = cpls x1  cpls x2  cpls1 x3 ….+ cplsn xn 
Equation 1. yE is the estimation of y; n is the number of grid points; cplsn is the PLS 
coefficient in the nth grid point; xn is the actual field in the n
th grid point.  
 
 
 
 
Table 4. Test set predictions and SDEP values obtained with models 1-
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  pEC50 
   predictedb 
Compd R expa M1 M2 M3 M4 M5 M6 
         
132 2-NO2 5.30 5.37 5.87 4.42 4.59 4.77 4.08 
133 2-NH2 4.96 5.96 5.89 5.33 5.58 5.76 5.39 
134 2-NO2-5-Cl 5.40 5.11 3.26 4.42 3.68 4.33 4.32 
135 2-NH2-5-Cl 6.00 6.43 2.70 5.28 4.52 5.74 3.82 
136 2-NO2-4-Cl 4.80 3.43 5.58 4.19 5.18 3.71 4.61 
137 2-NH2-4-Cl 4.13 3.79 5.56 3.81 5.35 3.54 5.28 
138 2-Cl-5-NO2 5.22 5.19 5.35 4.68 5.50 5.12 4.53 
139 2-Cl-5-NH2 3.82 6.31 6.23 5.56 6.39 5.96 5.55 
SDEPTest-Set   1.09 1.31 0.88 1.29 1.08 1.25 
Table 4 aExperimental pEC50 (pEC50 = -log EC50 (M)). 
bPredicted pEC50: M1 = model 1, M2  = 
model 2, M3 = model 3, M4 = model 4, M5 = model 5, M6 = model 6. 
 
Equation 1 may help the interpretation of Figure 18. The cpls coefficients are needed for 
predictions of the biological activity of new molecules. However, since the sizes and signs of 
the coefficients reveal the relative influence of each grid point on y, they are also suitable for 
the interpretation. That is, a new compound with a substituents protruding into a region with 
negative cplsr produces a positive (repulsive) field xr in this region. 
 
  
Figure 17. Fitting (up) and cross-validation (down) plots of the model 3 with two principal 
components. 
 
 
Consequently cpls xr is negative, thus indicating a negative influence on yE (a low pEC50 
corresponds to low affinity). The opposite is valid if the region has positive or negative cpls 
coupled with positive or negative fields, respectively.  
One important feature of 3-D QSARs is the graphical representation of the model, which 
makes its interpretation easier. In the GOLPE software, several options are available to 
display the final model. Among these, the PLS Coefficients and the Activity contribution 
plots are very useful. The PLS Coefficients plot (cpls) allows the visualization of the selected 
grid points at determined molecules/probe interaction energy level, indicating graphical 
information of the whole training set. However, in this plot the signs of the coefficients can 
induce errors, as reported with eq.1, coefficients have opposite meaning depending on the fact 
that the compound produces positive or negative field values in a specific area ( cpls x1  cpls x2 
). On the other hand, the Activity contribution plot gives the possibility to display spatial 
regions that are individually important for the selected molecule. The activity contribution 
plot, different for every molecule within the training set, results from multiplying the values 
of the coefficients by the actual values of the field for that molecule (yA) (yA = cpls x1  cpls x2) 
In Figure 18 the negative (red contours) and positive (blue contours) PLS coefficients are 
superimposed to 19e (the most active derivative, EC50 = 0.001 μM) and 40 (one of less active 
compounds, EC50 = 1.2 μM) activity contribution plots (positive contribution in yellow 
polyhedron and negative contribution in cyan) and a 4Å core of the NNBS.  
The contemporary representation allows an easy appreciation of important interactions on 
the basis of polyhedrons’ disposition and size. The most important differences were 
associated with the polyhedrons around the 3,5-dimethylphenyl moiety and the sulphonyl 
bridge at position 3 of the indole. The presence of two yellow areas around 19e’s 3,5-
dimethylphenyl moiety (positive activity contribution) highlighted the importance of 
hydrophobic interactions with this group. In contrast, unfavourable (yellow polyhedrons) 
interactions were recorded for the poorly active derivative 40. A further inspection of the PLS 
plots revealed the S  SO2 interchange as second important feature. Sulphone derivatives 
displayed a yellow area (positive contribution) around the sulphonyl group, while the sulphur 
counterparts lacked any positive contribution in the same region. Other positively contributing 
areas were observed in the proximity of the indole NH and the C-2 side chain. The presence 
of these polyhedrons in both highly and poorly active derivatives proved that these 
interactions are a minimum requisite in order to display some biological activity.  
 
 
Figura 18. Stereo view of the PLS coefficients. Polyhedron in red are negative coeff. 
(data level = -0.008), polyhedron in blue are positive coeff (data level = +0.008). Are 
also reported the activity contribution plots for 19e (Figure 7A, carbon atoms in 
white) and 40 (Figure 7B, carbon atoms in magenta). Positive contribution (data level 
= +0.035) to the activity is yellow polyhedron. Negative contribution (data level = -
0.035) to the activity is cyan polyhedron. 
 
6.2.3 Design of new IASs through molecular modelling and 3-D 
QSAR studies 
 
Merck’s findings147 suggested that little chemical modification at the indole-2-
carboxamide may lead to derivatives endowed with improved anti-HIV-1 activity against the 
drug-resistant mutant strains140. In addition, we found that insertion of 1-3 aminoacid units as 
chain elongators of the 2-carboxamide led to new potent IAS derivatives141. Therefore, we 
modelled 24 new IAS structures characterized by the presence of 2-[N-(2-
hydroyethyl)]aminocarbonyl or 2-[N’-(2-hydroyethyl)]hydrazinocarbonyl groups at the 
indole-2-position (92-115) (Table 5).  
The modelled IAS derivatives 92-115 were structure-based aligned as above described, to 
predict the associated pEC50 values. Among them, four compounds predicted as the most 
active (carboxamides 102 and 103, and carbohydrazides 112 and 115) along with 
carboxamide 92 and carbohydrazide 108 predicted as the least active derivatives, were 
synthesized and tested for their anti-HIV activity. Although the 3-D QSAR model was 
slightly under-predictive (Table 5), the predicted pEC50s showed the same trend of the 
experimental values. Deeper inspection of the 92, 102, 103, 108, 112 and 115 docked 
conformations allowed disclosing an alternate binding mode compared with that of 11. In 
particular, although we observed a 180° rotation of the indole nucleus (Figure 19), the 
interaction pattern was very similar to that already observed for the previous IASs. The 
benzene rings of the new compounds 92, 102, 103, 108, 112 and 115 were practically 
overlapped to that of 11 inside the NNBS aromatic rich pocket, and the hydrogen bond with 
Lys101 was also maintained. These observations confirmed our hypothesis claiming the 
correct accommodation of the aryl ring and the hydrogen bond with Lys101 crucial 
requirements for the anti HIV-1 activity. Furthermore, we found that the alternative binding 
mode of the new IASs was associated with a hydrogen bond formed between the terminal OH 
and the carbonyl of Leu234 (that is one of the most conserved residues of NNBS142) (Figure 
19). We correlated the under-predictive behaviour of the 3-D QSAR model to the limited 
chemical variability of the training set, and consequently to the presence of unexplored spaces 
around the training set and inside the NNBS.  
Regarding the low predicted (pEC50 < 7) designed IAS, inspection of derivatives 93, 96, 
108 and 114 Autodock3 poses revealed different and not optimal binding modes  that could 
account for the lower predicted pEC50. On the other hand the low pEC50 predicted sulphurs 
compounds 92, 94-95, 97, 104-107 and 109, although displaying binding modes similar to the 
corresponding higher pEC50 predicted sulphones (100-103 and 110-115), lack of some 
interactions with the Val106, Val179 and Lys103 small hydrophobic pocket. 
 
Table 5. pEC50 Predictions of 2-[N’-(2hydroyethyl)]carboxamide 
and 2-[N’-(2-hydroyethyl)]carbohydrazide IAS Derivative 
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Compd Structure X R 
predicted 
pEC50 
92 A S H 5.93 
93 A S 2-Me 5.96 
94 A S 3-Me 6.00 
95 A S 4-Me 6.54 
96 A S 2,3-Me 5.97 
97 A S 3,5-Me 6.41 
98 A SO2 H 6.76 
99 A SO2 2-Me 6.32 
100 A SO2 3-Me 7.05 
101 A SO2 4-Me 7.11 
102 A SO2 2,4-Me 7.13 
103 A SO2 3,5-Me 7.53 
104 B S H 6.49 
Compd Structure X R 
predicted 
pEC50 
     
105 B S 2-Me 6.70 
106 B S 3-Me 6.12 
107 B S 4-Me 6.55 
108 B S 2,4-Me 6.16 
109 B S 3,5-Me 6.62 
110 B SO2 H 7.06 
111 B SO2 2-Me 7.10 
112 B SO2 3-Me 7.36 
113 B SO2 4-Me 6.98 
114 B SO2 2,4-Me 6.65 
115 B SO2 3,5-Me 7.79 
Table 5 
 
Table 6. Predicted pEC50 and SDEPPred-Set value of selected compounds 
 pEC50 
Compd expa predb 
92 6.98 5.93 
102 8.00 7.13 
103 9.00 7.53 
108 5.64 6.16 
112 8.00 7.336 
115 8.00 7.73 
SDEPPred-Set - 1.00 
      Table 6 aTest Set experimental values. bTest Set prediction values 
 
 
 Figure 19. Comparison between 11 (cyan) and 103 (atom type) binding modes. Blue 
lines represent the hydrogen-bonds with Lys101 (in red, left side) and Leu234 (in red, 
right side). A 4 Å core of NNBS is displayed (black lines). Hydrogen atoms are omitted 
for sake of clarity.  
 
Table 7. Antiviral activities 
 
 
  EC50 (M)  
Compd wtIIIB Y181C Y181C- 112 AB1 
K130N 
103 0.0008 0.009 0.3 0.05 0.01 
115 0.001 0.04 3.2 0.055 0.07 
NVP 0.05 14 >20 >20 >20 
EFV 0.003 0.01 0.2 >20 >20 
 
Table 7. Antiviral activities of 103 and 115 against HIV WT, and Y181C and K103N-
Y181C mutant strains. The activities against the clinical isolates 112 and AB1 are also 
reported.  
 
 
6.3 Cross-docking experiments into mutated RTs 
Progress made in binding mode of IAS derivatives suggested to extend these studies 
towards the mutated forms of RT. Docking and cross-docking studies were carried out of the 
most active derivatives 103 and 115 into the WT RT, and the single (Y181C, K103N) and 
double (Y181C-K103N) mutated forms 143. WT (PDB entry code 1VRTWT/NVP
136; PDB entry 
code 1FK9WT/EFV 
128), Y181C (PDB entry code 1JLBY181C/NVP
136; PDB entry code 
1JKHY181C/EFV
144) and K103N (PDB entry code 1FKPK103N/NVP
145; PDB entry code 
1FKOK103N/EFV
146) experimental RT coordinates in complex with either NVP or EFV were 
promptly available. Y181C-K103N RT was extracted from 1JKH (K103N RT) structure by a 
virtual point mutation of the Tyr181 to Cys181. It was obtained introducing a virtual point 
mutation in an Y181C mutated RT.(PDB entry code 1jkh) Coordinates of second mutated 
residue was selecting from a K103N mutated RT (PDB entry code 1FKO)146 Both RT used 
were obtained by crystallography technique, it present high value of resolution (1FKO 2,5Ǻ; 
1FKO 2.9 Ǻ) and it were co-crystallized with the same inhibitor (efavirenz). 
After alignment, performed by ProFit, 1jkh Lys103 coordinates residue was substituted 
with 1fko Arg103 coordinates. At this point alignment procedure was repeated. The 
minimization, necessary to optimized complex structures was performed with Sander module; 
the partial atomic charges were derived by Antechamber module. 
The root mean square of deviation (RMSD) for all the heavy atoms between the binding 
modes of 103 and 115 in either 1VRT (NVP/RTWT complex) or 1FK9 (EFV/RTWT complex) 
extracted NNBSs, and those in 1JLQ (739W94/RTWT complex)
131 confirmed our findings 
(103: RMSD1VRT-1JLQ = 1.918; RMSD1VRT-1JLQ = 1.646. 115: RMSD1VRT-1JLQ_11 
= 1.098; RMSD1VRT-1JLQ = 1.613). The cross-docked binding modes of 103 and 115 in 
RTWT did not change with respect to those previously reported 
137. Again, crucial interactions 
were observed between Leu234 and OH of the 2-hydroxyethyl chain (Figure 19). Either 103’s 
or 115’s 2-hydroxyethyl chains fitted into the NNBS entrance channel formed by Val106, 
Pro225, Phe227, Leu234, His235, Pro236 and Tyr318, thus making both steric and 
electrostatic contacts.  
The Tyr181 ➔ Cys181 mutation weakly affected the Autodock proposed 103/115 binding 
modes, and showed conformations close to those observed for the RTWT (Figure 20). The 103 
bound conformations in either NVP/RTY181C or EFV/RTY181C derived NNBSs were closely 
related to those obtained from the corresponding RTWT. Differently, the docked conformation 
of 115 into NVP /RTY181C enzyme was slightly shifted, likely due to a less effective 
anchorage of the molecule inside the NNBS. We assumed that this difference may contribute 
to the poorer activity of compound 115 against the Y181C mutation (compare 103 and 115 
EC50s in Table 7).  
Lipophylic calculations revealed higher ALOGPs 145 value for 103 (2.31) compared to that 
of 115 (ALOGPs = 1.66). These observations suggested addressing their different biological 
activity to other factors, such as membrane permeability. Switching Lys103 ➔ Arg103 led to 
different results with respetct to the Y181C mutation. In NVP/RTK103N, both compounds 
showed only little modification of the RTWT binding modes (RMSD NVP /K103N/103 =1.167; 
RMSD NVP /K103N/115 = 1.947). On the contrary, the in EFV/RTK103N mutation thse compounds 
did not show RTWT-like binding modes (as showed by high RMSD values (>5.5) for both 
derivatives) (Figure 21); a wider cross-docking study is ongoing to confirm these data, taking 
in to account also the new mutated structure deposited in Protein Data Bank.. 
 
  
A B 
Figure 19. Docked conformations of 103 (green) and 115 (white) in the 1VRT (A) and 1FK9 (B) 
WT NNRTI binding pockets. Coloured in atom type and displayed in stick are the non-mutated 
Lys103 and Tyr181. Hydrogen’s atoms are not displayed for sake of clarity. 
 
The contemporary mutation of Tyr181 ➔ Cys181 and Lys103 ➔ Arg103, displayed 
different docked conformations from those observed for the single mutated Y181C or K103N 
RTs. In the double mutant, IAS 103 displayed a binding mode similar to that of L-737,126 in 
RTWT, while derivative 115 showed a different disposition (Figure 22). Such differences may 
account of 103’s higher activity against this double mutant strain. In addition these findings 
are in agreement with our observations123: a fixed binding mode of the molecule positively 
affects the activity against mutated RTs. 
 
  
A B 
Figure 20. Docked conformations of 103 (green) and 115 (white) as found by Autodock in the 
1JLB (A) and 1JKH (B) Y181C mutated NNRTI binding pockets. Colored in atom type and 
displayed in stick are the non-mutated Lys103 and the mutated Tyr181➔Cys181 residues. 
Hydrogen’s atoms are not displayed for sake of clarity. 
 
Compounds 103 and 115 were also evaluated against the HIV-112 and HIV-AB1 strains. 
The 112 strains was isolated from patient treated with NRTIs/NNRTIs based regimens, and 
carried K103N-V108I-M184V RT mutations that lead to >99% resistance to NVP and EFV. 
The AB1 strain was obtained after HAART treatment and carried the L100I-V108I RT 
mutations responsible of >90% and >85% resistance to NVP and EFV, respectively. 
Interestingly, both compounds were active at nano molar concentration against either HIV-
112 or HIV-AB1 strains (Table 7).  
 
 
  
A B 
Figure 21. Docked conformations of 103 (green) and 115 (white) in the 1FKP (A) and 
1FKO (B) K103N mutated NNRTI binding pockets. Coloured in atom type and 
displayed in stick are the mutated Lys103➔Arg103 and the unchanged Tyr181 residues. 
Hydrogen’s atoms are not displayed for sake of clarity. 
 
  
 
 
 
Figure 22. Docked conformations of 103 (green) and 115 (white) as found by Autodock 
in the K103N-Y181C modeled NNRTI binding pocket. Colored in atom type and 
displayed in stick are the mutated Lys103 ➔ Arg103 and Tyr181 ➔ Cys181 residues. 
Hydrogen’s atoms are not displayed for sake of clarity.  
 
 
6.4 The second improved 3-D QSAR model 
 
One of the main goals of the medicinal chemists is to improve the predictive ability of the 
model. To this end, the initial training set is enriched with new experimental information, 
thus starting over the cycle of designing new potential drugs.  
 
6.4.1 Definition, prediction ability and interpretation 
The above reported 3-D QSAR model was characterized by an under-predictive 
behaviour (Figure 13A). The limited number of molecules in the training set (limited 
chemical diversity) may be a possible explanation. While attempting to overcome this 
problem, we developed a new 3-D QSAR model by increasing the number of molecules in 
the training set from 70 to 101148. In particular the new training set was obtained by using 
the old test and prediction sets (eight and twenty-three compounds respectively, Tables 3 
and 4) The addition of molecules bearing different substituents at the 2-carboxamide 
function boosted the predictive ability of the previous model. 
As for the first 3-D QSAR studies, the statistical indexes r2, q2 and SDEP were employed 
to measure the goodness of the update model (Table 7). To determine the model 
dimensionality (number of optimal principal components, PCs) and hence evaluate its 
robustness, three cross-validation levels were employed: the leave one out (LOO) method 
and two leave some out (LSO) methods. Either five randomly selected groups (leave five 
out, L5O) or the extreme two randomly selected groups (leave half out, LHO) were used. 
The final new 101 objects composed a 3-D QSAR model which was defined by three PCs 
and r2, q2 LOO, q2 LFO and q2 LHO values equal to 0.90, 0.79, 0.78 and 0.73, respectively. 
Comparing these statistical values with those of the precedent model (r2 = 0.85 and q2 = 
0.63), the updated model highlighted its higher robustness and predictivity power (Table 8). 
For any 3-D QSAR model, an external test taken in addition to the internal validation (cross-
validation) is mandatory to really evaluate its predictive ability. To this end, a test set of 
eight hybrid IAS-peptide derivatives was compiled 141 (Table 9). The chemical composition 
of the TS was suitable (i) to measure the predictive power of the new model, and (ii) to 
compare its under-predictivity with that of the previous model. As expected, the new 3-D 
QSAR model was highly predictive and the under-predictive behaviour almost disappeared 
(Figure 23B, Table 9).  
 
 
Table 8. Statistical Values of the 2nd 3-D QSAR Model 
 
    LOO LOO L5O L5O LHO LHO 
FFD Vars PC r2 q2 SDEP q2 SDEP q2 SDEP 
0 3834 2 0.69 0.51 1.16 0.49 1.18 0.43 1.25 
1 1690 2 0.77 0.66 0.96 0.65 0.97 0.60 1.05 
2 1178 2 0.81 0.72 0.88 0.71 0.90 0.66 0.97 
3 942 2 0.84 0.76 0.81 0.75 0.83 0.70 0.91 
4 840 2 0.86 0.78 0.77 0.77 0.78 0.72 0.88 
5 802 3 0.90 0.79 0.75 0.78 0.77 0.73 0.86 
6 740 3 0.90 0.81 0.72 0.80 0.74 0.75 0.83 
7 729 3 0.90 0.81 0.72 0.80 0.74 0.75 0.83 
 
 
Table 9. Test set structures, ALOGpS values, and pEC50 predictions 
 
N
H
SO2
Y
Cl
O  
Compd Y 
ALOGpS 
(mg/L) 
Exp. 
pEC50 
New 
Pred. 
pEC50 
Old 
Pred. 
pEC50 
 
116 GlyNH2 -4.72 8.222 9.093 7.584 
117 GlyNHNH2 -4.53 8.000 9.044 7.543 
118 GlyGlyNH2 -4.69 7.222 8.081 4.082 
119 GlyGlyNHNH2 -4.50 7.097 5.933 7.649 
120 GlyAlaNHNH2 -4.64 7.854 7.641 4.875 
121 GlyAlaNH2 -5.07 6.921 7.346 7.503 
122 GlyGlyGlyNH2 -4.69 6.745 5.988 6.388 
123 GlyGlyGlyNHNH2 -4.43 9.155 7.897 5.386 
Table 9. Test set structures, ALOGpS values, and pEC50 predictions using the updated 3-D 
QSAR model (New Pred). For comparison purpose the predictions of the previous model are 
shown (Old Pred).  
 
 
As a measure of the improved prediction ability, the test set standard deviation error of 
prediction (SDEPTS) was calculated for both the old and new models; the updated 3-D QSAR 
showed a SDEPTS value of only 0.89, while for the old one the same coefficient was 2.05 
(Table 10). In particular the old model reported 118 and 120 as false negatives (Figure 23B) 
in the high micromolar range of concentration. In contrast, the new model correctly predicted 
the antiviral activity at low (120) and sub-micromolar (118) concentrations. It is worthy to 
note, using the IAS-peptide set the new model correctly predicted the overall activity trend, 
while the old one did not (Figure 23B, Table 9).  
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Figure 23. A: plot of prediction set pEC50 experimental and predicted values of the old 3-D 
QSAR model. B: plot of test set pEC50 experimental and predicted values of the new 3-D 
QSAR model. 
 
Table 10. Comparison of statistical coefficients and predictive 
ability 
 
Model PC r2 q2 L5O SDEPCV-L5O SDEPTSa 
Old 2 0.85 0.68 0.95 2.05 
New 3 0.90 0.78 0.77 0.89 
 
Table 10. Comparison of statistical coefficients and predictive ability between old and 
new 3-D QSAR models    aThe same test set reported in table 13 was used for either 
models 
 
The graphical potentiality of the GOLPE program was used for model interpretation. In 
Figures 23 and 24 are shown the PLS coefficients, present field (A and B of Figure 23) and 
activity contribution (C and D of Figure 23) plots for compounds 95 and 103. From Figures 
23 (PLS coefficients plot) it is evident the homogeneous distribution of the positive (cyan) 
and negative (yellow) FFD selected grid points around the training set, almost without any 
uncovered areas. This result is an important source of information although such a crumbling 
of the PLS polyhedrons makes model interpretation hard. To overcome this difficulty, the 
model analysis was focused on the molecular structure, and the PLS coefficient polyhedrons 
(Figures 23) were divided into three areas: (i) a group around the 3-aryl moiety (blue circle); 
(ii) a group near the 5-chloroindole nucleus (magenta circle) and (iii) a group surrounding the 
2-carboxamido/hydrazido group (green circle). Although 95 and 103 exhibited some 
similarity in chemical structure, both the structure-based alignment and the PLS algorithm 
successfully contributed to rationalize their 150-fold EC50’s difference. From both the PLS 
coefficients and present field plots, 103’s 3,5-dimethylbenzene moiety showed polyhedrons 
that correlated with favourable interactions into the NNBS aromatic rich sub-pocket (yellow 
polyhedrons with positive activity contribution in Figures 24). On the other hand, 95’s 4-
methylbenzene was slightly shifted and turned the same interaction into less favourable 
contacts (less yellow polyhedrons in Figure 24B). Regarding the 5-chloroindole moiety 
(magenta circled areas of Figure 23) no differences were observable for both 95 and 103; the 
two indole rings were perfectly superimposed each other, and the 5-chloroindole of 95 
showed favourable interactions through both the chlorine atom and the indole ring (compare 
PLS coefficients and activity contribution plots of Figures 23 and 24). The most important 
feature of the new 3-D QSAR model resided in the third group of polyhedrons (green circle in 
Figures 23). In fact, a comparison with the previous model in this area showed the greater 
differences that shed light on the possible role of the hydroxyethyl groups of either 95 or 103 
and all their related analogues.  
 
 
Figure 23. PLS-coefficient plot. Polyhedrons in yellow are negative coefficients (data 
level = -0.008); polyhedrons in cyan are positive coefficients (data level = +0.008);  
Compounds 103 (yellow) and 95 (red), and some relevant RT key residues are also 
displayed 
Both the GOLPE125 plots and Autodock3121 conformations attached importance not only 
to the 2-hydroxyethyl group, but also to its relative orientation into the NNBS. Again, the PLS 
coefficients correctly predicted that the OH group of 103 was optimally oriented to make 
electrostatic interactions (yellow polyhedrons in right side of Figure 24A; we hypothesized H 
bond between 103’s OH and Leu234; OH105…O=CLeu234 = 2.8Å, Figure 25). While the 
hydroxyl group of 95 displayed a different orientation. This group avoided the formation of 
any hydrogen bond and made unfavourable interaction with Pro225; it is underlined by the 
small yellow field preceding the big cyan one (B, D vs C, E in Figure 25).  
   
A B 
  
C D 
Figure 24. A and B: Present field plots. In yellow are negative fields (data level = 2.4), in 
cyan are positive fields (data level = +5.0). C and D: Activity contribution plots. In yellow 
are negative contributions (data level = -0.035), while in cyan are positive (data level = 
+0.035).A and C is the high active representative 103, in B and D the less active 95.  
  
A  
  
 
B C  
Figure 25. (To be continued)  
  
 
D E  
Figure 25. A: Comparison of 103 (cyan) and 95 (red) binding modes. B and C: Present 
fields plots focalized on the 2-hydroxyethyl groups of 103 (B, left) and 95 (C, right). D 
and E: Activity contribution plots focalized on the 2-hydroxyethyl groups of 103 (D, 
left) and 95 (E, right).  
 
 
 
 
6.4.2 Design and activity prediction of new IASs 
To ascertain whether the new model would predict untested derivatives, we designed eight 
new IASs (124-131) characterized by unreported structural modifications at the 2-
carbohydrazide group of 115 (Char t12 and Table 11)148.  
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Chart 12. Design of new IAS derivatives.  
 
 
 
Apart from the goal of validating the new procedure, the new compounds 124-131 were 
also designed to confirm the importance of the free hydroxyl groups of either 103 or 115. In 
fact, binding mode analyses indicated that their 2-hydroxyethyl moieties lay in an 
hydrophobic pocket mainly formed by the side chains Val106, Pro225, Phe227, Leu234 and 
Pro236 (see Figures, 19 and 25A). Such an observation suggested the introduction of less 
hydrophilic substituents at the 2-carbohydrazide moiety of 5 (Table 11). Taking into account 
the contribution of sterical interactions, the size of the substituents was varied from the small 
methyl to the bulky cyclohexyl groups. Interestingly, prior of any quantitative application, the 
binding modes proposed by Autodock gave some anticipation of their potential anti-HIV-1 
activities. Weaker anti-HIV activities were qualitatively predicted for 126 which showed a 
novel alternative binding mode different from either the initial reference compound L-
737,126 or 103 and 115 
This different binding mode led to hypothesize loss of important favourable interactions. 
The other seven designed IASs displayed binding modes comparable to that of 103 that 
allowed easier qualitative considerations. Derivative 124 was expected to be less active than 
103 due to the unsubstituted 3-phenyl ring120, even if the oxazolidinone ring of this compound 
fulfilled the hydrophobic pocket (Figure 25A). 
 
 
 
 
 
 
 
Table 11. Structure, predicted and experimental activity 
 
 
H
N N
H
N
O
Cl
SO2
R
O
O
H
N N
H
H
N
X
O
Cl
SO2
R
A B  
 
    pEC50 
Compd Structure R X Pred. Exp. 
124 A H - 7.446 7.824 
125 A 3,5-Me2 - 7.442 9.046 
126 B 3,5-Me2 Me 6.540 7.699 
127 B 3,5-Me2 iso-Pr 8.455 9.155 
128 B 3,5-Me2 cyclo-He 6.578 7.301 
129 B 3,5-Me2 COMe 8.139 8.301 
130 B 3,5-Me2 COOEt 6.234 7.699 
131 B 3,5-Me2 CONHNH2 7.134 8.000 
Table 11. Structure, predicted and experimental activity (pEC50) of designed 
compounds 124-131.  
 
The corresponding 3,5-dimethyl derivative 125 assumed almost the same binding mode of 
124, and according previous SARs, it was expected to be more active than 124. Designed 
derivatives 127, 129 and 131 (isopropyl, acetyl and hydrazinocarbonyl groups, respectively) 
optimally fulfilled the pocket formed by Val106, Pro225, Phe227, Leu234 and Pro236 
residues. Consequently these compounds were expected to be highly active.  
Regarding compounds 128 and 130, some unfavourable steric clashes were observed. The 
cyclohexyl or carboxyethyl residue (not shown) forced of the whole molecule to shift, and 
caused the disruptions of favourable interactions, such as the π−π stacking interaction of the 
3,5-dimethylbenzene with Tyr181 and Tyr188 and the hydrogen bond between the indole NH 
and Lys101. 
The qualitative prediction of 124-131’s activity by SBDD was successfully confirmed by 
the application of the second IAS 3-D QSAR model. Interestingly, the average predicted anti-
HIV-1 activity was about 60 nM and pressed their synthesis and biological evaluation. As 
qualitative (SBDD) and quantitative (LBDD) predicted, the designed new IASs revealed to be 
effectively highly active against HIV-1 acutely infected MT4 cells (Table 11). Again, the new 
derivatives were found more active than those predicted with an average pEC50 of 8.12 (EC50 
about 10 nM), and interestingly two compounds (125 and 127) showed sub-nanomolar anti-
HIV-1 activity (Table 11). In conclusion the new and updated 3-D QSAR model was fully 
successful. While expanding the IAS chemical diversity, the model increased its prediction 
ability and proved to be an efficient tool to discover new more potent and selective IASs.  
 
 Figure 26. Docked conformations of the designed IASs 124-131 (124: purple; 125: light 
green; 126: green; 127: orange; 128: blue; 129: grey; 130: dark green; 131: cyan). For 
comparison purposes the conformation of reference compounds con 103 (red) e 115 
(yellow) are also reported.  
 
 
 
 
6.5 The third 3-D QSAR model on HIV WT IASs and the first 
models on Y181C and K103N-Y181C HIV strains 
 
By the means of classical and computational medicinal chemistry techniques, our research 
group made extensive studies on sulphone containing NNRTIs that led to the discovery of 
very potent anti-HIV IASs (Chart 13)  
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WT 
1 
0.0008 
2 
0.0007 
Y181C 0.009 0.04 
K103N-Y181C 0.3 8.6 
Chart 13. The most potent published IASs. The EC50 is reported in M against 
the WT, Y181C and K103N-Y181C HIV strains.. 
 
Continuing our research on new anti-HIV agents and making a strong use of the in house 
biological data, we have developed new 3-D QSAR models specific for the wild type and two 
mutated RT isoforms (Y181C and K103N-Y181C). The new models revealed highly 
predictive and supported the synthesis of new unreported IASs derivatives characterized by 
the presence of various substitution patterns either at the indole nucleus or at the side 2 
carboxyl chain (compounds 3-10, Table 12). Experimental data, in agreement with the 
computational predictions, revealed the new IASs 3-10 to be very potent against both wild 
type and drug resistant mutants, and disclosed new lead compounds as starting point for the 
development of potential more potent anti-HIV IAS generations. 
6.5.1 3-D QSAR studies open strategies 
 
Continuing from the previous reported studies148,143 a more robust and predictive 3-D 
QSAR model specific for the HIV-1 wild type (3-D QSARwt) strain was developed. In 
parallel, two further 3-D QSAR models were also built for the Y181C mutant (3-D 
QSARY181C) and K103N-Y181C double mutant (3-D QSARK103N-Y181C) strains, respectively. 
 
 
Table 12. Newly Designed IASs Derivatives. 
 
N
H
Y
X
S
O
O
H
N
O
Z
 
 
Comp X Y Z  
3 NO2 - CH2CH2CH2SO2NH2 
4 Cl - CH2(CH3)CONHNH2 
5 Cl  CH2(CH3)CONH2 
6 F F H 
7 Cl - CH2(CH2OH)CONHNH2 
8 Cl - CH2(CH2OH)CONH2 
9 Cl - CH2CH2-1midazol-1-yl 
10 NO2 - CH2(CH2OH)CONH2 
 
 
 
 
6.5.2 Training Sets Composition and Alignment Rules 
For the 3-D QSARwt model a training set (TrSet) of 117 IASs derivatives was compiled by 
adding to the last previous training set (101 derivatives) the test (8 hybrid IAS-peptide 
derivatives) and prediction (8 IASs characterized by the presence of pyrrolidyn-2-one nucleus 
at the indole-2-carboxamide or bearing some substituents at the indole-2-carbohydrazide) data 
sets (Table 13). For the 3-D QSARY181C and 3-D QSARK103N-Y181C models the same TrSet was 
used (Table 13) comprising all IAS derivatives (40 for both models) for which biological anti-
HIV activities against the single (Y181C) and the double (K103N-Y181C) mutants strains 
were available.  
The training sets were structure-based (SB) aligned by means of docking experiments. 
The wild type TrSet was docked into the NNBS extracted from the 739W94/RT complex; the 
Y181C TrSet was docked into the NNBS extracted from the Efavirenz/RTY181C complex
144 
(pdb entry code 1jkh) and finally for the K103N-Y181C TrSet SB alignment a modeled RT 
double mutant was used. 
The good results obtained with old models were for us the better confirm to continue to 
use program GOLPE92 using as dependent variable the inverse of the logarithm of the 
experimental anti-HIV-1 activities (pEC50s) and as independent variables the molecular fields 
generated by the means of the GRID93 software using the water (OH2) probe.  
 
Table 13. Structures, WT, Y181C and K103N-Y181C Anti-
HIV-1 µM Activities of Training Set Compounds Used for the 3-D 
QSARs. 
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H
X
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 NH
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A B C 
Com
p. 
 X Y Z W 
EC50 (M) 
WT Y181C 
K103N 
Y181C 
11 A SO2 H NH2 Cl 0.001 0.02 8 
20 A S H OEt H 1.4 - - 
21 A S 2-NH2 OEt H >200 - - 
22 A S 2-NH2-5-Cl OEt H ≥200 - - 
23 A S 2-NH2 OEt Cl 2.3 - - 
 
 
24 A S 2-NH2-5-Cl OEt Cl 2.5 - - 
25 A SO2 H OEt H 3.7 - - 
Com
p. 
 X Y Z W 
EC50 (M) 
WT Y181C 
K103N 
Y181C 
26 A SO2 2-NH2 OEt Cl >200 - - 
27 A SO2 2-NH2-5-Cl OEt H 2.5 - - 
28 A SO2 2-NH2-5-Cl OEt Cl 1.9 - - 
29 A S H NH2 H 1.4 - - 
30 A S 2-NH2-5-Cl NH2 H 9 - - 
31 A S H NH2 Cl 0.02 4 >9 
32 A S 2-Me NH2 Cl 0.3 - - 
33 A S 4-Me NH2 Cl >0.45 - - 
34 A S 4-F NH2 Cl 1.4 - - 
35 A S 4-Cl NH2 Cl 3.1 - - 
36 A S 4-iso-Pr NH2 Cl 1.9 - - 
37 A S 4-tert-Bu NH2 Cl 8 - - 
38 A S 3,5-Me2 NH2 Cl 0.006 >0.7 >0.7 
39 A S 2,6-Cl2 NH2 Cl 1.2 - - 
40 A S 2-NH2-5-Cl NH2 Cl 1.6 - - 
41 A SO2 H NH2 H 0.18 - - 
42 A SO2 2-NH2-5-Cl NH2 H 0.3 - - 
19a A SO2 2-Me NH2 Cl 0.001 0.16 10 
19b A SO2 3-Me NH2 Cl 0.001 0.006 7 
19c A SO2 4-Me NH2 Cl 0.003 0.02 >100 
43 A SO2 4-F NH2 Cl 0.014 - - 
44 A SO2 4-Cl NH2 Cl 0.011 - - 
45 A SO2 4-iso-Pr NH2 Cl 0.08 - - 
46 A SO2 4-tert-Bu NH2 Cl 0.13 - - 
Com  X Y Z W EC50 (M) 
p. 
WT Y181C 
K103N 
Y181C 
19d A SO2 2,4-Me2 NH2 Cl 0.004 0.15 10 
19e A SO2 3,5-Me2 NH2 Cl 0.004 0.03 0.6 
47 A SO2 2,6-Cl2 NH2 Cl 0.1 - - 
48 A SO2 2-NH2-5-Cl NH2 Cl 0.04 - - 
49 A SO2 3,5-Me2 NH2 Br 0.002 0.015 0.55 
50 A SO2 3,5-Me2 NH2 COMe 0.015 0.18 >100 
51 A SO2 3,5-Me2 NH2 CH(OH)Me 0.025 0.05 >100 
52 A S H NHNH2 Cl 0.55 - - 
53 A S 4-Me NHNH2 Cl 1.5 - - 
54 A S 4-F NHNH2 Cl 5 - - 
55 A S 4-Cl NHNH2 Cl 10 - - 
56 A S 2-NH2-5-Cl NHNH2 Cl >13 - - 
57 A SO2 H NHNH2 H 0.53 - - 
58 A SO2 H NHNH2 Cl 0.01 0.4 >100 
59 A SO2 4-Me NHNH2 Cl 0.05 - - 
60 A SO2 4-F NHNH2 Cl 0.32 - - 
61 A SO2 4-Cl NHNH2 Cl 0.19 - - 
62 A SO2 3,5-Me2 NHNH2 Cl 0.13 2.5 >10 
63 A SO2 2-NH2-5-Cl NHNH2 Cl 0.3 - - 
64 B SO2 H H H >150 - - 
65 B SO2 4-Cl COOEt H >100 - - 
66 B SO2 2-NO2 COOEt H 1.8 - - 
67 B SO2 2-NO2-5-Cl COOEt H >100 - - 
68 B SO2 2-NH2-5-Cl COOEt H 1.8 - - 
Com
p. 
 X Y Z W 
EC50 (M) 
WT Y181C 
K103N 
Y181C 
69 B SO2 H H 3-COOEt >32 - - 
70 B SO2 H H 3-COO-i-Pr >54 - - 
71 B SO2 H H 5-Cl >75 - - 
72 B SO2 H COOEt 5-Cl >200 - - 
73 B SO2 4-Me COOEt 5-Cl >200 - - 
74 B SO2 4-Cl COOEt 5-Cl >200 - - 
75 B SO2 2-NO2-5-Cl COOEt 5-Cl >31 - - 
76 B SO2 2-NH2-5-Cl COOEt 5-Cl 8.3 - - 
77 B SO2 H H 5-Cl-3-COOEt >42 - - 
78 B SO2 H H 5-Cl-3-COO-iPr >200 - - 
79 B SO2 H CONH2 H 15 - - 
80 B SO2 H CONHNH2 H >200 - - 
81 B SO2 H CONH2 5-Cl 66.6 - - 
82 B SO2 H H 3-CONH2 >32 - - 
83 B SO2 H H 5-Cl-CONH2 ≥200 - - 
132 B - 2-NO2 - - 5.30 - - 
133 B - 2-NH2 - - 4.96 - - 
  134 B - 2-NO2,5-Cl - - 5.40 - - 
135 B - 2-NH2, 5-Cl - - 6.00 - - 
136 B - 2-NO2, 4-Cl - - 4.80 - - 
137 B - 2-NH2, 4-Cl - - 4.13 - - 
138 B - 2-Cl, 5-NO2 - - 5.22 - - 
139 B - 2-Cl, 5-NH2 - - 3.82 - - 
92 A S H NHCH2CH2OH 5-Cl 0.04 - - 
Com
p. 
 X Y Z W 
EC50 (M) 
WT Y181C 
K103N 
Y181C 
93 A S 2-Me NHCH2CH2OH 5-Cl 0.05 - - 
94 A S 3-Me NHCH2CH2OH 5-Cl 0.08 - - 
95 A S 4-Me NHCH2CH2OH 5-Cl 0.12 - - 
96 A S 2,3-Me2 NHCH2CH2OH 5-Cl 0.10 - - 
97 A S 3,5-Me2 NHCH2CH2OH 5-Cl 0.012 0.6 1.2 
98 A SO2 H NHCH2CH2OH 5-Cl 0.001 0.07 4.2 
99 A SO2 2-Me NHCH2CH2OH 5-Cl 0.031 1.2 12 
100 A SO2 3-Me NHCH2CH2OH 5-Cl 0.003 0.08 1.1 
101 A SO2 4-Me NHCH2CH2OH 5-Cl 0.043 - - 
102 A SO2 2,4-Me2 NHCH2CH2OH 5-Cl 0.008 - - 
103 A SO2 3,5-Me2 NHCH2CH2OH 5-Cl 0.0008 0.009 0.3 
104 A S H NHNHCH2CH2OH 5-Cl 0.2 - - 
105 A S 2-Me NHNHCH2CH2OH 5-Cl 0.1 - - 
106 A S 3-Me NHNHCH2CH2OH 5-Cl 0.17 - - 
107 A S 4-Me NHNHCH2CH2OH 5-Cl 0.6 - - 
108 A S 2,4-Me2 NHNHCH2CH2OH 5-Cl 1.2 - - 
109 A S 3,5-Me2 NHNHCH2CH2OH 5-Cl 0.03 1.0 6.7 
110 A SO2 H NHNHCH2CH2OH 5-Cl 0.01 1.2 >20 
111 A SO2 2-Me NHNHCH2CH2OH 5-Cl 0.05 0.1 >20 
112 A SO2 3-Me NHNHCH2CH2OH 5-Cl 0.007 0.2 20 
113 A SO2 4-Me NHNHCH2CH2OH 5-Cl 0.04 1 >20 
114 A SO2 2,4-Me2 NHNHCH2CH2OH 5-Cl 0.08 0.04 3.2 
115 A SO2 3,5-Me2 NHNHCH2CH2OH 5-Cl 0.001 0.05 0.8 
116 A SO2 3,5-Me2 Gly-NH2 5-Cl 0.006 0.03 0.8 
Com
p. 
 X Y Z W 
EC50 (M) 
WT Y181C 
K103N 
Y181C 
117 A SO2 3,5-Me2 Gly-NHNH2 5-Cl 0.01 0.05 2 
118 A SO2 3,5-Me2 GlyGly-NH2 5-Cl 0.0007 0.005 1.2 
119 A SO2 3,5-Me2 GlyGly-NHNH2 5-Cl 0.06 0.08 2.8 
120 A SO2 3,5-Me2 GlyAla-NH2 5-Cl 0.014 0.03 2.2 
121 A SO2 3,5-Me2 GlyAla-NHNH2 5-Cl 0.08 0.16 3.55 
122 A SO2 3,5-Me2 GlyGlyGly-NH2 5-Cl 0.12 0.23 5.9 
123 A SO2 3,5-Me2 GlyGlyGly-NHNH2 5-Cl 0.18 0.33 >11.1 
124 C SO2 H  5-Cl 0.015 0.3 20 
125 C SO2 3,5-Me2  5-Cl 0.001 0.01 0.9 
126 A SO2 3,5-Me2 NHNHCH3 5-Cl 0.05 0.13 >20 
127 A SO2 3,5-Me2 NHNH-i-Pr 5-Cl 0.0007 0.04 8.6 
128 A SO2 3,5-Me2 NHNH-c-He 5-Cl 0.1 1.2 >20 
129 A SO2 3,5-Me2 NHNHCONHNH2 5-Cl 0.04 0.02 5.7 
130 A SO2 3,5-Me2 NHNHCOCH3 5-Cl 0.005 0.02 >20 
131 A SO2 3,5-Me2 NHNHCOOEt 5-Cl 0.02 0.04 9.2 
 
6.5.3 3-D QSARwt model 
A final robust 3-D QSAR model was achieved with only 3 principal components (PCs) 
characterized by r2 value of 0.90 and leave one out (LOO), five group (L5O) and leave half 
out (LHO) q2 values (q2LOO, q
2
L5O and q
2
LHO) corresponding to 0.83, 0.81 and 0.76 and LOO 
L5O and LHO SDEP (SDEPLOO SDEPL5O SDEPLHO) values of 0.70, 0.73 and 0.82, 
respectively (Table 14). Compared to the 3-D QSAR model reported on 2006148 an 
improvement of the statistical coefficient was obtained, such an improvement is even greater 
if one compare the actual model statistical coefficients with those of the very first model 
reported on 2005137 (Table 14) 
Table 14. Statistical coefficients of the actual 3-D QSAR model 
compared to those of the previously reported models. 
 Vars 
PC
s 
r2 
LOO L5O LHO 
q2 SDEP q2 SDEP q2 SDEP 
Actual Model 1024 3 0.90 0.83 0.70 0.81 0.73 0.76 0.82 
JMC 2005 Model164 669 2 0.85 0.69 0.94 0.68 0.95 0.64 1.00 
JMC 2006 Model187 802 3 0.90 0.79 0.75 0.78 0.77 0.73 0.86 
 
One important feature of 3-D QSAR studies is the graphical representation of the 
models, which allows making its easier interpretation. In the actual model, the variable 
number to get the optimal 3-D QSAR was greater than in the precedent two models and this 
features (Table 14) allowed to display more defined PLS polyhedrons leading to an even 
easier interpretation of the PLS maps that the program GOLPE generates. Similarly as 
previously reported 148,137 the PLS pseudo-coefficients and the activity contribution plots 
were used for the model interpretation.  
 
Figure 27.Two rotated views (top and bottom) of PLS coefficients (Polyhedrons in 
yellow are negative fields (data level = -0.008), polyhedrons in cyan are positive fields 
(data level = +0.008). The high active IAS representative X (displayed as by atom type 
colour) is also reported. A 4Å core of the NNBS is also displayed. 
 
Derivative 103 one of the most active IASs, was used as reference compound to interpret 
the 3-D QSAR maps. The analysis of the PLS coefficients and the activity contribution plots 
lead the polyhedrons to be reduced into four key groups (Figure 27): 
1. a group around the dimethylphenyl portion (red circles in Figure 27); 
2. a group around the chlorine atom in position 5 of indole ring (green circles in 
Figure27); 
3. a group around N1 of indole nucleus(black circles in Figure 27); likely this field could 
be referred to the H-bond with Lys101carbonyl oxygen (Figure 29). 
4. a group around the side chain attached in indole position 2 (blue circles in Figure 27). 
This analysis is similar to that previously reported148 in which only three main polyhedron 
groups were identified. Nevertheless, the greater number of variables led to better defined 
maps relative to the 5-Cl and N1 atoms that could clearly be divided in two groups (green and 
black circles in Figure 27).  
Respect to the previous model (JMC 2006 Model)148 the main polyhedrons shape and 
dimension differences were recorded around the carbonyl and hydroxyl oxygens of indole 
side chains and closely to the 5-Cl atom (Figure 28B). Recalling that the TrSet was SB 
aligned the use of the NNBS helped the correlation of the 3-D QSAR results with the 
potential ligand/receptor interactions. The role of the electrostatic interaction described109 
between the terminal 103 hydroxyl and the conserved Leu234137main chain carbonyl was also 
observed for the very most active IAS 118 (EC50 0.0007 μM, Table 13 and Figure 27 and 29).  
 
 
Figure 28. 119 and 103 PLS coefficient plots. Polyhedrons (contours) in yellow are 
negative fields (data level = -0.008), polyhedrons in cyan are positive fields (data level 
= +0.008). In surface style are highlighted the fields relative to indole side chains 
carbonyl and hydroxyl oxygen and relative to chlorine atom. 
 
Interestingly the 118 hydrazide analogue 119 showed a different binding mode (BM) 
(Figure 29). This 119 BM adjustment could be ascribed to the length of the side chain and the 
presence of a “wall” formed by Leu234, His235, Pro225 and Phe227 residues. In 119 the 
further nitrogen atom makes the side chain too long to be accommodated in the same space of 
118 glycine moiety thus forcing the molecule to an alternative BM, that while keeping the 
dimethylphenyl moiety supeimposable to that of 119 and the hydrogen bond between the 
indole NH with the Lys101 carbonyl oxygen, disrupt a strong hydrogen bond (Figure 29), 
leading to an activity decrease (119 EC50 = 0.06 μM) correctly incorporated in the 3-D QSAR 
model. Regarding the above further two PLS coefficients differences (see areas around 5-Cl 
and 2-C=O in Figures 29 and Figure 30.) between the actual and previous model a detailed 
inspection did not identify any relevant interaction. For the 118 carbonyl oxygen’s no 
hydrogen bonds were visible with any residue around a distance of 4Å. The same space is 
occupied by the 119 chlorine atom, so that the interactions are likely steric in nature. Similar 
conclusion can be drawn out for the type of interaction occurring in the Pro95, Glu138B and 
Asn136B residues region. In this area either the 118 5-Cl or the 119 terminal portion of the 
C2 side chain of indole are not involved in any relevant interaction. 
 
 
 Figure 29. 118 (carbon atoms in cyan) and 119 (carbon atoms in orange) docked 
conformations. A 5Å core of the 1jlq NNBS is also reported in wire style. “Wall” 
residues (see text) are reported in stick. Potential H-bond are reported in black dashed 
lines (NHRS1919
…
O=CLys101 = 3.3 Å;  CONH2RS1919
…
O=CLeu234 = 2.3 Å; 
NHRS2068
…
O=CLys101 = 3.3 Å. 
 
 
  
  
Figure 30. Details on the differences between the previous (right column) and the actual 
models (left column) PLS coefficients plots. The RS1675 (1) structure is displayed for 
interpretation. 
 
 
6.5.4 3-D QSARY181C model characteristic and interpretation 
 
The same procedure used to build the 3-D QSARwt model was adopted. Optimal variables 
selection was achieved after only three FFDs, leading to 602 active variables. The final model 
was characterized by high-quality statistical indexes values with only 3 PCs (r2 = 0.94, q2L5O 
= 0.68, SDEPL5O = 0.42; Figure 31). Additional FFD selections led to slight statistical 
improvements, nevertheless a much reduced containing variables model often prove to be 
useless in predicting the dependent variable (biological activity)  
For the 3-D QSARY181C model analysis and interpretation the PLS pseudo coefficients 
(Figure 31), activity contribution (Figure 32) and present field (Figure 33) plots relative to 
19e (EC50-Y181C 0.006 M), 19c (EC50-Y181C 0.03 M), 19d (EC50-Y181C 0.02M) and 19a 
(EC50-Y181C 0.16M) were used. Differently from the well characterized WT model, in this one 
the use of a series of compounds differently substituted on the phenyl ring is of some utility in 
highlighting dissimilar polyhedrons spatial arrangements that correlate with the role of 
mutation Tyr181 to Cys181 and hence with the activity differences against the RTY181C 
variant. Comparing the 19a, 19e, 19d and 19c structure based aligned conformations (Figure 
31) the inhibitor binding modes seem highly dependent from both the Tyr181  Cys181 
mutation and the position of the methyl group on the phenyl ring. 
 
 
 Vars PCs r2 
L5O 
q2 SDEP 
3-D QSARY181C 602 3 0,94 0,68 0,42 
 
  
Figure 31. Fitting (left side) and Cross-validation (right side) Plots of the Y181C 
Model with 3 PCs. 
 
 
 
 
The Y181C NNBS cavity is therefore able to discriminate the different phenyl 
substitutions and this was correctly identified by the 3-D QSARY181C model. Differently as 
observed for the WT model the PLS coefficients polyhedrons cannot be easily divided into 
groups, in fact the structure based alignment were rather different and not comparable each to 
other and, as a consequence a different PLS polyhedron distribution was observed. At the 
±0.0045 data level the displayed PLS coefficients are mainly negative (cyan polyhedrons, 
Figure 31) and only three main small yellow maps groups (positive coefficients) are present. 
Two of the latter’s (around the methyl’s groups on the 19a, 19e, 19d and 19c benzene rings 
and close to the indole moiety) are associated to positive values of the OH2 GRID fields and 
could explain some sterical repulsive interactions between the IASs methyl substituents and 
the Pro95, Cys181 and Trp229 residues and the C6-C7 indole carbon atoms with the Lys101 
methylene side chain (Figure 31). 
 
 
Figure 31. 3-D QSARY181C PLS coefficients plot. 19a (cyan), 19e (grey), 19d 
(magenta) and 19c (green) docked conformations into RTY181C are displayed. 
Polyhedrons in yellow are negative fields (data level = -0.0045), polyhedrons in cyan 
are positive fields (data level = +0.0045). A 4Å core of the Y181C NNBS is also 
displayed for easer interpretation. 
 
On the other hand, the third yellow coloured maps group, associated to negative GRID 
field values, situated in the proximity of the 2-carboxyamide groups, are involved in hydrogen 
bonding interactions with His235 and/or Pro236 main chain carbonyl oxygen’s and/or Tyr318 
hydroxyl (electrostatic attractive interactions). Others small yellow polyhedron are also 
visible in Figure 31, but any trials to interpret them was useless. Regarding the cyan 
polyhedrons in Figure 31 (negative PLS coefficients), the most important are a couple around 
the area that correspond to the two amidic hydrogens. In fact, these two polyhedrons are 
characterized by lower values of PLS coefficients that modulate the corresponding GRID 
fields; depending on the signs of the latter’s a positive (negative GRID fields) or negative 
(positive GRID fields) contribution to the activity is associated to the above areas (Figure 32). 
In this scenario for the four representative IASs 19a, 19e, 19d and 19c as displayed in Figures 
31, 32, 33 and 34, the methyl substituents seem to play a crucial role. 
In particular from Figure 31, taking as reference the docked structure the most active IAS 
19e, which bear a methyl in position meta, it is possible to observe that a second meta methyl 
group or a single ortho methyl substitution are responsible of the inhibitor molecule shift (to 
the left in Figure 9) likely caused by the steric clashes with either Tyr188 and Phe227 (19a) 
or Trp229 (19c) side chains. 
A more severe influences is exerted by the meta  para modification (19e  
19d); the 19d para-methylphenyl group being less bulky than the 19e meta-
methylphenyl can enter in a NNBS small sub-pocked formed by Pro95, Cys181 and 
Trp229 residues with an overall binding mode that is the result of even greater 
molecular shift (to the right of Figure 31).  
 
  
A B 
Figure 32 To be continued 
 
 
 
 
 
 
C D 
Figure 32. Activity contribution plots relative to 19a (A), 19e (B), 19d (C) and 19c 
(D). A 4Å core of the Y181C NNBS is also displayed for interpretation. 
 
 
 
 
 
 
  
A B 
  
C D 
Figure 33: Present field plots relative to 35(A), 36 (B), 37 (C) and 43 (D). Polyhedrons are 
associated to OH2 GRID field values. Sign is positive in yellow polyhedrons, while are 
negative in cyan polyhedrons.  
The 19a, 19e, 19d and 19c different binding modes, once encoded into the 3-D QSAR 
model (alignment rules) were quantitatively described and diverse activity contribution plots 
have been obtained for each compound (Figure 32), thus reflecting the experimental 
biological activity values. A deeper inspections of the activity contribution plots in Figure 32 
led to point the attention around the carboxyamide moiety, were the maximum polyhedron 
location and dimension variability can be observed consistently with the above PLS 
coefficients plot interpretation. In fact, while for 19e two hydrogen bonding distances are 
present between the amide nitrogen and HIS235 main chain carbonyl oxygen and Tyr318 
hydroxyl group (NRS1720
…O=CHis235 = 3.0 Å; NH2RS1720
…O-PhenylTyr318 = 3.0 Å; Figure 35), 
only one possible hydrogen bond can be recorded for 19a, 19d and 19c  (Figure 35). It could 
be argued that 19c is more than five times more active than 19a while sharing the same 
binding mode; nevertheless the orto-methyl is involved in repulsive interactions with Phe227 
as confirmed by the negative contribution polyhedrons (Figure 32B). 
 
 
 
Figure 34. View of 19a (cyan), 19e (grey), 19d (magenta) and 19c (green) docked 
conformations into the Y181C NNBS (1jkh) 
 
 
 
 
Figure 35. 19e (carbon atoms in cyan) and 19c (carbon atoms in orange) docked 
conformations. A 4Å core of the 1jlq NNBS is also reported in wire style. Potential 
H-bond are reported in black dashed lines 
 
 
 
6.5.5 3-D QSARK103N-Y181C model characteristic and interpretation 
 
The same Y181C model (3-D QSARY181C) training set of 40 molecules was used to build 
the 3-D QSAR model relative to the K103N-Y181C double mutant anti-HIV activities. A 
protocol similar to those used for the two previous described models (3-D QSARWT and 3-D 
QSARY181C) was employed for the molecule alignment, GRID calculations and model 
refinements (data pre-treatment, FFD selections). TS molecules were aligned by means of 
docking experiments using as receptor a modelled K103N-Y181C mutated RT. The final 3-D 
QSARK103N-Y181C model was derived after a number of FFD selections with only 1 PCs and 
displaying r2 , q2L5O and SDEP values of 0.74, 0.55 and 0.52, respectively (Figure. 36).  
The docked conformation of derivative 103, the most active IAS against the double mutant 
HIV strain (Table 1), was used to aid the interpretation of the subsequent reported PLS 
coefficients and activity contributions plots (Figure 37). Differently from the previous two 
models a straightforward interpretation can be drawn out from the plots in Figure 37. In the 
PLS coefficients plot three groups of polyhedrons can be related to the di-methylphenyl, 5-
halogen indole and 2-hydroxyethyl carboxyamide side chain respectively (Figure 38A). These 
three moieties are related to positive activity contributions (Figure 37B) that well correlate 
with the corresponding ligand/receptor interactions obtained by the SB alignment. 
 
 Vars PCs r2 
L5O 
q2 SDEP 
3-D QSARK103N-Y181C 673 1 0,74 0,55 0,52 
 
  
Figure 36: Fitting (left side) and Cross validation (right side) Plots of the K103N-Y181C 
Model with 1 PCs. 
 
 
In particular the di-methylphenyl moiety lay in a aromatic rich hydrophobic pocket formed 
by Cys181, Tyr188, and Trp229, the 5-chloroindolyl fulfils another pocket formed by Pro235 
Tyr318 and Leu234 side chains (Figure 37) and finally two hydrogen bonding distances were 
recorded between the hydroxyethyl OH group from the Lys101 and the side chainN and 
between the indole N1 and Lys101 carbonyl oxygen (Figure 37). A support of the importance 
of the latter interactions, compound 19c, lacking of the hydroxyethyl group and having a 
similar docked conformation is less active.  
 
A1  B1  
Figure37 (To be continued) 
A2  B2  
A3  B3  
Figure37 PLS coeff (1), Activity Contribution (2), and Field (3) of 103 (A) and 19c (B). 
6.5.6 Prediction 
 
Thanks to the 3-D QSAR analysis, we have designed and predict different series of new 
IASs. The plots generated by GOLPE suggest us to modify molecular function were 
polyhedrons interpretation got the great number of information. For the tree models analyzed 
these moieties are: the side chain in position 2 and chlorine atom in position 5 of indole. In 
particular our attention was focused on the substitution of chlorine atom with bromine or nitro 
group, and the contemporary di-substitution in position 4-5, 4-6, 5-6 and 5-7 on indole 
nucleus with chlorine and fluorine atoms. On the other hand we have to evaluate the effect of 
modification of side chain with introduction of one or more units of both natural and non-
natural amino-acids and the substitution with heterocyclic aromatic and non aromatic. The 
prediction set was about 100 compounds. The conformation of each was obtained repeating 
docking procedure used for the training set  
 
 
 
Table15.1: Di-Halogen Derivatives 
 
N
H
SO2
NHZ
O
Y
X
 
 
Comp X Y Z WT Y181C 
K103N-
Y181C 
140 5,6-Cl2 H H 5.91 7.15 3.84 
141 5,6-Cl2 3,5-Me2 H 6.1 6.9 4.6 
142 5,6-Cl2 3,5-Me2 CH2CH2OH 8.25 7,17 5.27 
143 5,7-F2 3,5-Me2 H 8.16 7.49 5.06 
144 5,6-F2 3,5-Me2 H 7.55 7.5 5.5 
145 4,5-F2 3,5-Me2 H 8.06 7.75 5.34 
146 6-Cl,5-F 3,5-Me2 H 6.43 7.2 5.57 
147 4-Cl,5-F 3,5-Me2 H 7.37 8.08 5.61 
148 5-Cl,6-F 3,5-Me2 H 6.42 6.71 5.64 
149 5-Cl,4-F 3,5-Me2 H 7.07 7.21 5.78 
150 5,6-F2 H H 6.07 6.88 4.81 
151 4,5-F2 H H 7.16 7.42 4.88 
 
 
New IASs molecules were separated into four different groups (Table15.1 15.5) using 
new introduced moiety to classify it. 
 
Table 15.2: Heterocyclic Derivatives 1 
 
N
H
Cl
SO2
H
N
O
X
Y
 
 
N
H
Cl
SO2
H
N
O
Y
X
 
A B 
Comp  X Y WT Y181C 
K103N-
Y181C 
152 A pyrrolidin-1-yl H 7.22 7.3 4.24 
153 A piperidin-1-yl H 8.12 6.46 4.85 
154 A pyrrolidin-1-yl 3,5-Me2 6,97 6,4 4,73 
155 A piperidin-1-yl 3,5-Me2 8,75 6,45 3,33 
156 A morpholin-4-yl 3,5-Me2 6,31 7,04 5,41 
157 A morpholin-4-yl 3,5-Me2 8,24 6,94 4,75 
158 B 2-Me-5-NO2-imidazol-1-yl 3,5-Me2 6,99 6,43 4,18 
159 B 2-Me-5-NO2-imidazol-1-yl H 6,77 6,88 5,29 
160 B 2-Me-5-NO2-imidazol-1-yl 3-F 7,41 6,27 5,46 
161 B 2-Me-5-NO2-imidazol-1-yl 3-Me 7,87 6,81 5,19 
162 B pyrrol-1-yl 3,5-Me2 8,17 6,71 5,84 
Comp  X Y WT Y181C 
K103N-
Y181C 
163 B 2-Me-5-NO2-imidazol-1-yl 3-Cl 7,85 6,5 3,91 
164 B 2-Me-5-NO2-imidazol-1-yl 3-OMe 7,29 6,43 4,83 
165 B phenyl 3,5-Me2 8,26 6,42 4,29 
166 B imidazol-1-yl 3,5-Me2 8,29 7,47 5,18 
167 B thiophen-2-yl 3,5-Me2 8,13 6,96 5,39 
168 B 4-Cl-phenyl 3,5-Me2 7,8 6,72 4,87 
169 B 2-Cl-phenyl 3,5-Me2 7,3 6,92 5,09 
170 B 3-Cl-phenyl 3,5-Me2 7,75 6,41 5,18 
171 B 2-Me-phenyl 3,5-Me2 8,03 6,48 5,78 
  172 B 3-Me-phenyl 3,5-Me2 7,8 6,44 4,55 
173 B 4-Me-phenyl 3,5-Me2 7,78 6,23 5,08 
174 B morpholin-4-yl 3,5-Me2 7,8 6,84 5,12 
175 B pyrrolidin-1-yl 3,5-Me2 7,71 7,29 4,54 
 
 
All the predicted pEC50 values were used to build a consensus model. Molecules for in 
vitro testing were selected with a rank-by-rank approach based on the predicted EC50 values 
of the three models. Compounds with lower rank sum should be active versus not only wild 
type but also against two analyzed mutant strains. These derivatives were selected to be 
synthesized and tested (Table 16) 
The analysis of wild type 3-D QSAR predicted biological activity values confirmed the 
goodness of model resulting a very powerful tool for activity prediction (Table 20A), Standard 
Deviation Errors of Prediction (SDEP) was 0.41. In particular compound RS1980S (Exp 8.20; 
Pre 8.82; EC50 0.003 µM) result active against wild type RT at -molar concentration. S 
refers to amino acid configuration that doesn’t change in condensation reaction. 
For not enantiomeric pure amino-acids, after condensation on indole nucleus, racemic 
moisture was resolved by chiral HPLC and single enantiomer was tested. New IASs binding 
mode into wild type RT NNBS study show two different  
 Table 2 15.3: Heterocyclic derivatives 2 
 
 
N
H
Cl
SO2
H
N
O Y
X
O
 
N
H
Cl
SO2
X
O  
A B 
Comp   X Y WT 
Y181
C 
K103N 
Y181C 
176 A  Morpholin-4-yl H 5.36 6.66 4.48 
177 A  Cyclo-propylamino H 7.94 6.51 4.55 
178 A  Tert-butylamino H 7.02 7.46 5.42 
179 A  Anilino H 7.62 6.77 4.8 
Comp   X Y WT 
Y181
C 
K103N 
Y181C 
180 A 
R 
NH2 CH2SH 
7.97 6.69 5.22 
S 7.46 6.08 5.27 
181 A 
R 
NHNH2 CH3 
8.10 7.25 4.82 
S 7.87 7.33 5.16 
182 A 
R 
NHNH2 CH2SH 
8.06 6.74 5.15 
S 7.36 6.56 4,75 
183 A 
R 
NH2 CH2OH 
7,86 7,48 5,47 
S 8.37 7.22 4.98 
184 A R NHNH2 CH2OH 8.55 7.04 4.24 
  S   8.19 7.73 5.13 
185 A  Gly-NHCH2CH2OH H 8.14 6.67 4.67 
186 A  Gly-N(CH2CH2OH)2 H 7.76 5.8 5.18 
187 A  
NHCH2CH2-1- 
(2-Me-5-NO2-imidazolyl) 
H 5,71 6.84 4,82 
188 A  Gly-NHCH2CH2-1- 
(2-Me-5-NO2-imidazolyl) 
H 5.46 6.58 4.31 
189 A  NHNHCH2CONH2 H 6.82 7.14 4.59 
190 A  NHNHCH2CONHNH2 H 7.1 7.14 5.16 
191 B  NH2 - 6.4 6.74 5.23 
192 B  NHCH2CONH2 - 6.42 6.86 4.89 
 
spatial dispositions into WT RT NNBS: 6 of 8 derivatives have the same BM of reference 
compound 103. Only derivatives (unexpected) 145 and 262 (one of less active molecule) 
showed indole nucleus rotated (Figure 38 A1-A2). 
Table 15.4: Nitro Derivatives 
 
 
N
H
Cl
R
NH2
O
Y
 
N
H
Cl
SO2
H
N
O Z
NH2
O
Y
 
N
H
Cl
SO2
N
O
O
NH2
Y
 
A B C 
Comp  R X Y Z WT 
Y181
C 
K103N 
Y181C 
193 A S 5-NO2 H - 5.24 6.54 5.48 
194 A SO2 5-NO2 H - 6.33 7.19 5.74 
195 A SO2 5-NO2 3,5-Me - 8.17 6.95 5.57 
196 B  5-NO2 3,5-Me CH2CH2SCH3 5.74 6.23 5.42 
197 B  5-NO2 3,5-Me CH2PH 6.91 6.13 4.68 
198 B  5-NO2 3,5-Me CH2-indol-3-yl 3.88 6.13 5.49 
199 B  5-NO2 3,5-Me CH2OH 7.85 6.92 4.42 
200 B  5-NO2 3,5-Me CH(CH3)2 6.77 6.78 4.76 
201 B  5-NO2 3,5-Me CH2CH(CH3)2 5.94 6.9 5.58 
202 B  5-NO2 3,5-Me  4.3 6.13 4.57 
203 C  - - - 5 6.99 4.6 
204 B  5-NO2 3,5-Me (CH2)2 6.38 7.02  5.32 
205 B  5-NO2 3,5-Me CH(CH3) 7.4 6.43 4.88 
206 A  5-pyrryl 3,5-Me - 5.93 6.53 5.35 
207 A  5-pyrryl 3,5-Me - 6.68 5.6 4.3 
Table 15.5: Amino Acids Derivatives 
N
H
SO2
NHR2
O
R1
 
Comp 
Abs. 
Conf 
R1 R2 WT Y181C 
K103N 
Y181C 
208 - 5-Br 
NH2
O
 
6.28 7.26 4.15 
209 - 5-NO2 6.9 6.54 5.57 
210 
R 
5-Cl 
NH2
O
CH3
D,L
 
8.92 7.32 4.9 
S 8.19 6.73 5.4 
5.45 6.74 5.06 
211 
R 
5-Br 6.05 6.69 4.88 
S 
4.5 7.45 5.44 
212 
R 
5-NO2 4.78 7.90 4.49 
S 
5.14 6.74 4.68 
213 
R 
5-Cl,4-F 6.03 6.39 4.99 S 
214 - 5-Cl 
NH2
O  
5.96 7.3 4.26 
215 - 5-Br 7.89 7.87 5.18 
6.38 7.02 5.32 
216 - 5-NO2 
5.77 8.02 5.26 
 
 
 
217 - 5-Cl,4-F 
5.18 6.73 4.79 218 R 5-Cl 
Comp 
Abs. 
Conf 
R1 R2 WT Y181C 
K103N 
Y181C 
 S  
CH3
D,L
O
NH2
 
3.4 6.74 4.35 
5.33 6.05 5.09 
219 
R 
5-Br 6.96 6.72 4.86 S 
6.98 7.04 4.95 
220 
R 
5-NO2 5.83 6.90 4.64 S 
221  5-Cl 
S
NH2
O O  
5.19 6.95 5.16 
222  5-Br 4.46 6.63 5.35 
7.22 7.82 5.04 223  5-NO2 
224 
R 5-Cl 
S
NH2
O OCH3
L
 
4.88 6.75 5.30 
S 5.24 7.25 5.82 
225 
R 5-Br 6.13 6.79 4.89 
S 7.56 6.27 4.56 
226  5-NO2 7.22 7.82 5.04 
 
The analysis of experimental and predicted anti-HIV activity values for Y181C model 
(Table 16B) showed that it was over-predictive with SDEP 1.27. A wide training set, (with 
new tested IASs), should improved model prediction ability. In spite of this the screening 
method permitted to select two compounds 262 and 210S active at the same concentration of 
reference 19e. 
 
 Table 16: Predicted Compounds 
 
  
A: Wild Type Model 
 
 
B: Y181C Model 
 
Comp WT EC50 
 Exp Pred 
262 8 7.82 
2043S 7.22 7.33 
210S 8.30 6.73 
145 5.77 7.75 
184S 6.70 7.73 
183S 5.82 7.22 
166 6.10 7.47 
199 5.59 6.92 
Comp WT EC50 
 Exp Pred 
262 7.45 7.22 
2043S 7.87 7.89 
210S 8.82 8.20 
145 7.52 8.06 
184S 7.40 8.19 
183S 8.52 8.37 
166 8.10 8.29 
199 7.77 7.85 
 Table 16: Predicted Compounds (Continued) 
 
 
C: K103N-Y181C Model 
 
 
The BM exploration of the new IASs showed two different spatial dispositions: 6 of 8 
derivatives poses as reference 19e and only two have indole nucleus rotated. These two 
compounds 262 and 199 were characterized by a nitro group in position 5 of indole. Probably, 
in NNBS of Y181C-RT isoforms, this function constrained molecules to this spatial 
disposition.  
 
 
 
 
 
 
Comp WT EC50 
 Exp Pred 
262 6.52 5.04 
2043S 6.52 5.16 
210S 6.14 5.40 
145 5.60 5.57 
184S 5.36 4.75 
183S 6.14 5.84 
166 5.72 4.67 
199 3.70 4.42 
  
 
 
 
A1 A2 
  
B1 B2 
  
C1 C2 
Figure 38 (To be continued) 
 
 
 
  
 
C1 C2 
  
 
 
 
Figure 38: Binding Mode of new IASs in wild Type, Y181C and K103N-Y181C 
RT binding site.  
 
 
The K103N-Y181C model showed under-predictive ability. Also for this model an 
extended training set should enhance the prediction capability, although among the selected 
derivatives three have biological activity values close to the reference compound. The BM 
analysis has given a dominant conformation (5 of 8) common to the most active molecules 
(103). 
 
 
183S 
184S 166 
145 262 
210S 
199 
2043 
 7. Conclusions. 
 
This thesis describes the progress made in the development of anti-HIV-1 indolyl aryl 
sulphones. Molecular modelling, docking and 3-D QSAR studies played a key role in this 
research. New and updated software allowed more refined SBDD and LBDD studies that 
gave a great contribution in understanding the possible binding mode of known IASs and the 
definition of highly predictive 3-D QSAR models. These findings guided the disclosure of 
new and more potent IAS series. The new IASs were potent inhibitors of the HIV-1 WT and 
clinically relevant mutant strains in both cellular-based and enzyme assays at nanomolar 
concentrations. These encouraging results did not quench our enthusiasm in searching for 
more and more new updated SBDD and LBDD based models. In particular new studies are 
ongoing aimed to design new compounds endowed with activity against the HIV-1 mutant 
strains. Therefore, specific SBDD and/or LBDD models will be soon developed using our 
accumulated activity data. 
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